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1. INTRODUCTION {#jcp29735-sec-0010}
===============

CoVs were recognized as "novel respiratory tract viruses" over half a century ago. The title was conferred in 1962, following the examination of samples collected from individuals who had manifested symptoms of respiratory tract infection (Hamre & Procknow, [1966](#jcp29735-bib-0036){ref-type="ref"}). Initially, CoVs were not considered as highly pathogenic for humans. That was until 2002, however, that CoVs emerged in the form of Severe Acute Respiratory Syndrome (SARS) in the Guangdong state of China (Sahin et al., [2020](#jcp29735-bib-0064){ref-type="ref"}). Almost a decade later, another highly pathogenic CoV appeared in the Middle East countries, which similarly led to severe respiratory symptoms of acute onset. The then‐novel species was named Middle East Respiratory Syndrome Coronavirus (MERS‐CoV; Zaki, Van Boheemen, Bestebroer, Osterhaus, & Fouchier, [2012](#jcp29735-bib-0092){ref-type="ref"}).

In December 2019, a cluster of insidious Coronavirus infections was reported in the Huanan Seafood Market, located in Wuhan State of Hubei Province in China. Unlike the name, livestock animals were also traded in the market alongside their marine relatives. Days later, the cluster turned into a local network and set off the alarm for the Chinese government. It was then that a pneumonia epidemic of unknown cause became the focus of global attention (Sahin et al., [2020](#jcp29735-bib-0064){ref-type="ref"}). Chinese authorities announced on January 7, 2020 that a new type of CoV (novel CoV, nCoV) was isolated (Imperial College London, [2020](#jcp29735-bib-0056){ref-type="ref"}; World Health Organization, [2020](#jcp29735-bib-0082){ref-type="ref"}). On December 12, 2019, a pneumonia case of unknown origin was reported in Wuhan, China. Initial laboratory tests ruled out Influenza and infection with recognized CoVs. Following the incident, 27 new cases of pneumonia of viral origin were officially reported on December 31, 2019. A week later on January 7, 2020, the Chinese authorities announced that a new species of CoV was isolated in the country (Zumla, Hui, Azhar, Memish, & Maeurer, [2020](#jcp29735-bib-0099){ref-type="ref"}).

Given the whereabouts of the first case ever reported, the infection was speculated to have been contracted from a zoonotic agent. Etiologic investigations on patients who had been hospitalized with a similar medical history supported the likelihood of a viral infection transmitted from animals to humans (Sahin et al., [2020](#jcp29735-bib-0064){ref-type="ref"}; World Health Organization, [2020](#jcp29735-bib-0082){ref-type="ref"}; Yin & Wunderink, [2018](#jcp29735-bib-0090){ref-type="ref"}). nCoV was duly reported to have been originated from wild bats. Falling in the category of group 2 β‐CoVs, the novel Coronavirus only shares a 70% similarity in genetic sequence with its predecessor, SARS‐CoV, which also belongs to the exact same family (Gralinski & Menachery, [2020](#jcp29735-bib-0034){ref-type="ref"}).

The tantalizing surge in the number of cases infected with SARS‐CoV‐2 in China, despite the closure of markets and evacuation of the vicinity, fulfilled the burden of proof that the virus can also be transmitted from human to human. Soon thereafter, peculiar cases of acute respiratory syndrome started appearing in other Asian countries, ultimately spreading to North America and Europe. (Sahin et al., [2020](#jcp29735-bib-0064){ref-type="ref"}; World Health Organization, [2020](#jcp29735-bib-0082){ref-type="ref"}; Yin & Wunderink, [2018](#jcp29735-bib-0090){ref-type="ref"}). Following an emergent briefing on January 30, 2020, The World Health Organization (WHO) declared the outbreak of COVID‐19 as a Public Health Emergency of International Concern (Organization, [2020](#jcp29735-bib-0080){ref-type="ref"}).

The epidemic began to emerge with the advent of the Chinese New Year, a traditionally important festival that is heavily celebrated across the country. The coincidence paved the way for SARS‐CoV‐2 to turn into an unprecedented massive Coronavirus outbreak, which required extensive measurements to be contained. With a population of 10 million, Wuhan City also served as an important pathway for millions of people traveling in celebration of the Spring Festival. Accordingly, the number of cases to be diagnosed with COVID‐19 showed an overwhelming increase between January 10--22, 2020 (Chen, Zhang et al., [2020](#jcp29735-bib-0017){ref-type="ref"}).

Despite the arbitrary speculations, not only did the recent outbreak of COVID‐19 egress the country of origin, it also proceeded to become a global concern in the form of a pandemic (Yang et al., [2020](#jcp29735-bib-0089){ref-type="ref"}). COVID‐19 is an acute self‐resolving respiratory disease in most of the cases, however, it can also be fatal in some cases. The disease was initially reported to have a mortality rate of 2%. If severe, COVID‐19 might result in death as a result of the preceding extensive alveolar damage, and failure of the lungs (Xu et al., [2020](#jcp29735-bib-0087){ref-type="ref"}). As of February 15, 2020, a total of 66,580 cases had been confirmed, with over 1,524 deaths. However, there have no specific reports on pathology, as performing an autopsy or biopsy was not possible in most of the cases (Chan et al., [2020](#jcp29735-bib-0010){ref-type="ref"}; Huang et al., [2020](#jcp29735-bib-0040){ref-type="ref"}). Table [1](#jcp29735-tbl-0001){ref-type="table"}. Represents the WHO situation reports on March 24, 2020 ([www.WHO.int](http://www.WHO.int)).

###### 

The number of cases and death of Covid‐19 outbreak according to World Health Organization statistics (April 13, 2020)

  Region                         Total (new) cases in last 24 hr   Total (new) death in last 24 hr
  ------------------------------ --------------------------------- ---------------------------------
  Globally                       1,773,084 confirmed (76,498)      111,652 deaths (5,702)
  Western Pacific Region         121,426 confirmed (1,310)         4,125 deaths (67)
  European Region                913,349 confirmed (33,243)        77,419 deaths (3,183)
  South‐East Asia Region         16,883 confirmed (842)            766 deaths (38)
  Eastern Mediterranean Region   99,713 confirmed (3,768)          5,107 deaths (164)
  American Region                610,742 confirmed (36,804)        23,759 deaths (2,228)
  African Region                 10,259 confirmed (531)            464 deaths (21)
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A total of 8,096 SARS cases and 774 deaths across 29 countries were reported for an overall case‐fatality rate (CFR) of 9.6%. MERS is still not contained and is thus far responsible for 2,494 confirmed cases and 858 deaths across 27 countries for a CFR of 34.4%. Despite the much higher CFR of 9.6% and 34.4% for SARS and MERS, the novel Coronavirus epidemic has led to a larger death toll. The Chinese government had reported 72,528 confirmed cases, with 1,870 deaths, as of February 18, 2020. These statistics yield a crude CFR of 2.6%. However, one should not haste to generalize this number, as most possibly the total number of patients with COVID‐19 is much higher. That is, because the cases are not readily identifiable, as many asymptomatic patients are missed during the process (Wu et al., [2020](#jcp29735-bib-0083){ref-type="ref"}; Yan et al., [2020](#jcp29735-bib-0088){ref-type="ref"}). Despite the higher transmissibility than SARS and MERS, COVID‐19 is still a relatively unknown disease and requires further investigations to be fully understood (Yan et al., [2020](#jcp29735-bib-0088){ref-type="ref"}).

2. PATHOGENESIS {#jcp29735-sec-0020}
===============

Initially, the virus interacts with sensitive human cells that exhibit distinct receptors for the viral Spike protein. After making a successful entry, the RNA‐based genome starts replicating itself, and expressing specific sequences that results in production of useful accessory proteins; facilitating the adaptation of CoV to its human host (ViralZone., [2019](#jcp29735-bib-0070){ref-type="ref"}). Alterations in genetic make‐up that result from recombination, exchange, insertion, or deletion of genes, are frequently reported among CoVs; a phenomenon that might have played a part in the past epidemics (Sahin et al., [2020](#jcp29735-bib-0064){ref-type="ref"}). Therefore, the classification of CoVs is continuously being changed. Based on the most recent classification provided by The International Committee on Taxonomy of Viruses, there are four genera of CoVs, that comprise a total of 38 unique species (Subissi et al., [2014](#jcp29735-bib-0067){ref-type="ref"}). Thus, variable mechanisms could be involved in the process of pathogenesis. For instance, SARS‐CoV binds to angiotensin I converting enzyme 2 (ACE2). On the other hand, MERS‐CoV is more inclined to attach the cellular receptor of dipeptidyl peptidase 4 (Lambeir, Durinx, Scharpé, & De Meester, [2003](#jcp29735-bib-0048){ref-type="ref"}). Following a cascade of signals after binding, the viral genome is successfully injected into the target cell. The genomic RNA that regulates the expression of structural and nonstructural polyproteins, is polyadenylated and encapsulated. These proteins are then cleaved by certain proteases that exhibit chymotrypsin‐like activity (Lambeir et al., [2003](#jcp29735-bib-0048){ref-type="ref"}; ViralZone, [2019](#jcp29735-bib-0070){ref-type="ref"}). Through replication and transcription, the resulting protein complex drives the production of negative‐sense RNA or (−) RNA. Full‐length (−)RNAs produced by replication are ultimately used as templates for generation of positive‐sense RNA or (+) RNA (Luk, Li, Fung, Lau, & Woo, [2019](#jcp29735-bib-0057){ref-type="ref"}; ViralZone, [2019](#jcp29735-bib-0070){ref-type="ref"}). All of the structural proteins are then translated from a subset of 7--9 subgenomic RNAs, which are products of discontinuous transcription. The resulting protein complex is the assembled together to envelope the viral genome, making a nucleocapsid in the process, that will bud into the lumen of the endoplasmic reticulum to finally complete the intracellular cycle. Newly formed virions are then expelled from the infected cell through exocytosis. The CoVs released thereafter are now capable to infect a wide spectrum of human cells, including lung, renal, hepatic, intestinal, and lower respiratory tract cells, as well as T lymphocytes (Chhikara, Rathi, Singh, & Poonam, [2020](#jcp29735-bib-0019){ref-type="ref"}; Lambeir et al., [2003](#jcp29735-bib-0048){ref-type="ref"}). Figure [1](#jcp29735-fig-0001){ref-type="fig"} presents a schematic of viral structure and the entry mechanism of SARS‐CoV‐2.

![Presents a schematic of viral structure and the entry mechanism of SARS‐CoV‐2](JCP-9999-na-g001){#jcp29735-fig-0001}

2.1. Respiratory system {#jcp29735-sec-0030}
-----------------------

SARS‐CoV‐2 tends to infect the respiratory tract, thus, pneumonia is a primary clinical finding in patients with COVID‐19 (Huang et al., [2020](#jcp29735-bib-0040){ref-type="ref"}; Li, Guan, et al., [2020](#jcp29735-bib-0051){ref-type="ref"}; Zhu et al., [2020](#jcp29735-bib-0097){ref-type="ref"}). However, pneumonia is only a component of the SARS that might develop in some cases. The resulting SARS may then be aggravated and lead to serious conditions that are extremely difficult to control, for example, septic shock, metabolic acidosis, and coagulation dysfunction (Kofi Ayittey, Dzuvor, Kormla Ayittey, Bennita Chiwero, & Habib, [2020](#jcp29735-bib-0045){ref-type="ref"}).

Investigation on the radiological findings of COVID‐19‐associated pneumonia have yielded little, if any, information that are mostly unspecific. Progressive lung lesions are usually detected in patients with COVID‐19, about 1 week after the onset of signs and symptoms (Ooi et al., [2004](#jcp29735-bib-0060){ref-type="ref"}). The lesions then become aggravated during the 2nd week, and lead to formation of irregular reticular opacities mixed with ground glass opacities (GGOs), which can be detected by CT at the fourth week. In a recent cohort study, 85.7% (54/63) of subjects with COVID‐19‐associated pneumonia showed disease progression, defined by an increased extent of GGO, on early follow‐up CT (Pan et al., [2020](#jcp29735-bib-0062){ref-type="ref"}). Pulmonary fibrous cords was reported in one particular patient that displayed signs of improvement, as the inflammatory secretions had been absorbed (Pan & Guan, [2020](#jcp29735-bib-0061){ref-type="ref"}). Long‐term complications of COVID‐19 in patients with severe pneumonia might include an array of fibrotic changes often observed in the late stages of lung injury, for example, reticulation, interlobular septal thickening, and traction bronchiectasis (Kim, [2020](#jcp29735-bib-0043){ref-type="ref"}).

2.2. Immune system {#jcp29735-sec-0040}
------------------

There have been several reports that indicated meager Cytolethal Distending Toxin‐induced lymphocytes, with a density as low as 200 cells/mm^3^ in three patients with SARS‐CoV infection (Chu et al., [2014](#jcp29735-bib-0024){ref-type="ref"}; Zhou et al., [2014](#jcp29735-bib-0096){ref-type="ref"}). As in the case of SARS‐CoV‐2, it has been suspected that infection with this type of CoV might lead to inflammatory cytokine storm (Chen, Liu, et al., [2020](#jcp29735-bib-0013){ref-type="ref"}; Zumla et al., [2020](#jcp29735-bib-0099){ref-type="ref"}); a life‐threatening condition characterized by elevated levels of interleukin 6 (IL‐6) in plasma. A number of investigations recently conducted on COVID‐19 have reported that IL‐6 levels was actually higher in the patients with severe disease (Cai, [2020](#jcp29735-bib-0008){ref-type="ref"}; Chen, Liu, et al., [2020](#jcp29735-bib-0013){ref-type="ref"}; Xiang et al., [2020](#jcp29735-bib-0102){ref-type="ref"}). This could highlight the importance of IL‐6 as a biomarker for evaluation of disease severity (Chen, Zhao, et al., [2020](#jcp29735-bib-0015){ref-type="ref"}).

2.3. Liver damage {#jcp29735-sec-0050}
-----------------

Impaired liver function tests have been reported for a number of patients with SARS‐CoV‐2 infection, suggesting hepatic damage as an extrapulmonary complication of COVID‐19 in almost one half of the patients (Chen, Zhou, et al., [2020](#jcp29735-bib-0014){ref-type="ref"}; Wang, Hu, et al., [2020](#jcp29735-bib-0072){ref-type="ref"}). A recent study has concluded that liver function abnormality might stem from infection of bile duct cells with SARS‐CoV‐2. Nonetheless, the alkaline phosphatase value, which is an index of bile duct damage, were not specific in patients with COVID‐19 (Chen, Zhou, et al., [2020](#jcp29735-bib-0014){ref-type="ref"}; Wang, Hu, et al., [2020](#jcp29735-bib-0072){ref-type="ref"}). Investigation of liver biopsy specimens was accompanied by new pathological findings. Scientists have reported moderate microvascular steatosis, and mild lobular and portal activity in these patients, that suggests liver damage may have arisen from either SARS‐CoV‐2 infection or drug‐induced liver (Xu et al., [2020](#jcp29735-bib-0087){ref-type="ref"}).

2.4. Myocardial, gastrointestinal, and renal symptoms: homeostasis of electrolytes {#jcp29735-sec-0060}
----------------------------------------------------------------------------------

An essential player in maintenance of electrolyte balance and blood pressure, ACE2 is regarded by many as the principal counter‐regulatory arm in the axis of renin--angiotensin‐aldosterone system (RAAS; Santos, Ferreira, & Simões e Silva, [2008](#jcp29735-bib-0065){ref-type="ref"}). Upon infection, SARS‐CoV‐2 binds ACE2. This results in degradation of ACE2, which subsequently dampens the counter‐effect of ACE2 on RAAS. The final effect of ACE2 in an otherwise healthy adult is to increase reabsorption of sodium and the reciprocal excretion of potassium ions (K^+^). The concomitant re‐uptake of water with sodium reabsorption prompts an increase in blood pressure (Weir & Rolfe, [2010](#jcp29735-bib-0075){ref-type="ref"}). Potassium is the predominant intracellular ion, that is majorly involved in regulation of cell membrane polarity. Too low levels of K+ in blood, known as hypokalemia, can result in cellular hyper‐polarity. A hyper‐polarized cell membrane tends to be depolarized faster than normal, causing aberrancy in the function of cardiac cells (Bielecka‐Dabrowa et al., [2012](#jcp29735-bib-0007){ref-type="ref"}).

In a recent cohort study, patients diagnosed with COVID‐19 were categorized into three groups: severe hypokalemia, hypokalemia, and normokalemia. The study reported that 93% of patients with a severe clinical condition had hypokalemia. Scientists did not find a direct link between gastrointestinal symptoms and hypokalemia among 108 patients with both severe or moderate hypokalemia. Further investigations established an association between parameters such as body temperature, creatine kinase (CK), creatine kinase myocardial band (CK‐MB), lactate dehydrogenase (LDH), and C‐reactive protein (CRP) with the severity of hypokalemia. Reportedly, hypokalemia was most often observed with patients who had elevated levels of serum CK, CK‐MB, LDH, and CRP. Potassium (K^+^) loss in the urine was determined to be the primary cause of hypokalemia.

Hypokalemia requires strenuous efforts to be corrected. This is chiefly due to the incessant loss of K^+^ in the urine, as a result of ACE2 degradation. In the case of COVID‐19‐associated hypokalemia, however, the patients seemed to respond well to potassium supplements when the critical phase had passed \[49\]. Therefore, one should consider the impact of hypokalemia in COVID‐19 morbidity, and its effect on the outcomes of treatment. This is a condition that must be carefully addressed for, as patients with COVID‐19 are more inclined to develop dysfunctions in heart, lungs, and other vital organs (Li, Hu, Su, & Dai, [2020](#jcp29735-bib-0052){ref-type="ref"}).

3. POSSIBLE FACTORS CORRELATED WITH COVID‐19 {#jcp29735-sec-0070}
============================================

3.1. Sex {#jcp29735-sec-0080}
--------

Several studies have sought to compare the sex differences in the clinical findings of severe COVID‐19. In one study, scientists investigated 47 patients with COVID‐19, 28 (59.6%) of whom were men. Procalcitonin (PCT) level was reported to be higher in men than in women. The results also showed higher amounts of serum N‐terminal‐pro brain natriuretic peptide, as increased levels of the molecule were detected in men 57.1% than women 26.3%. Furthermore, 17.9% of male patients were reported test‐positive for influenza A antibody, whereas no such records were registered for female patients. During a 2‐week stay at the hospital, 17.9% of male, and 5.3% of female patients deteriorated, and hence were reassigned to the critical‐type group. There was no mortality reports among women, whereas 3.6% of male patients had deceased due to COVID‐19 complications. A total of 21.1% and 3.6% of female and male patients successfully recovered, and were discharged from the hospital. Based on the current evidence, men are more likely to develop complications, and experience worse in‐hospital outcomes compared with women (Li, Zhang, et al., [2020](#jcp29735-bib-0050){ref-type="ref"}).

3.2. Pregnancy {#jcp29735-sec-0090}
--------------

A group of researchers led by Chen investigated the clinical characteristics of SARS‐CoV‐2 infection in nine pregnant women. Their aim was to evaluate the likelihood of intrauterine/vertical transmission of SARS‐CoV‐2 from mother to baby. All of the women who were being investigated had cesarean section in the third trimester of their previous pregnancies. Seven patients were febrile, and variably presented other symptoms such as cough, sore throat, myalgia, and malaise. Fetal distress was reported in two cases. Lymphopenia and increased aminotransferase activity were observed in five and three patients, respectively. There was no mortality cases, as none of the patients in the study developed severe COVID‐19‐associated pneumonia. Nine livebirths were recorded. The newborns displayed no signs of asphyxia. A 1‐min Apgar score of 8--9, and a 5‐min Apgar score of 9--10 were calculated for all nine newborns. Samples collected from six patients, including amniotic fluid, cord blood, neonatal throat swab, and breastmilk proved test‐negative for SARS‐CoV‐2. The clinical features of COVID‐19‐associated pneumonia observed in these pregnant women shared a great similarity to characteristics reported for COVID‐19‐associated pneumonia in nonpregnant adult patients (Chen, Guo, et al., [2020](#jcp29735-bib-0011){ref-type="ref"}).

3.3. Blood type {#jcp29735-sec-0100}
---------------

In a recent investigation, scientists in China looked into the pattern of blood type distribution in 2,173 patients in three hospitals, who had been confirmed to have SARS‐CoV‐2 infection. Accordingly, they compared their findings regarding the blood type of patients with that of the healthy population who lived in the same area as the patients in the study. Apparently, there was a higher prevalence of blood type A among the patients with COVID‐19 than in the normal population. On the contrary, it seemed that individuals with O blood type were spared somehow, as there were fewer patients with this blood type in this study (both *p* \< .001). A series of meta‐analyses on the available data indicated a significantly higher risk for COVID‐19 in people with blood type A, relative to individuals with non‐A blood types. However, an opposite scenario seemed to be true for the blood type O community, since, according to the literature, are less susceptible for contracting infectious diseases such as COVID‐19 (Zhao et al., [2020](#jcp29735-bib-0095){ref-type="ref"}).

4. ETIOLOGY: SOURCES AND MODES OF TRANSMISSION {#jcp29735-sec-0110}
==============================================

According to the literature, the pathogen and area of origin were similar in both SARS and COVID‐19 outbreaks. However, despite this similarity, the raised public awareness and extensive interventional procedures that might have once proved effective for SARS containment, have been rendered ineffective against the 2019 novel Coronavirus; as the disease is already more widespread than SARS (Liu, Gayle, Wilder‐Smith, & Rocklöv, [2020](#jcp29735-bib-0055){ref-type="ref"}). A large family of viruses, CoVs are common among many different animal species, including cattle, civets, camels, and bats. However, these CoVs are not solely restricted to animal populations, as they can occasionally infect humans, bringing epidemics such as SARS, MERS, and in recent memory, COVID‐19 (Sahin et al., [2020](#jcp29735-bib-0064){ref-type="ref"}). Recent investigations conducted on the origins of CoVs responsible for the past epidemics have reported bats as the primary reservoir for both SARS‐CoV and MERS‐CoV; suggesting that other animal species were involved in the process merely as intermediate hosts. Accordingly, the majority of bat‐associated CoVs belong to α‐CoV and β‐CoV genera, while almost all of the avian CoVs fall in the other two genera; γ‐CoVs and δ‐CoVs (Yin & Wunderink, [2018](#jcp29735-bib-0090){ref-type="ref"}). It has been suggested that species responsible for the recent epidemic is reminiscent of the CoV isolated in bats. Trafficking of wild animals in Huanan Seafood Market, located in Wuhan State of Hubei Province in China, where the first cases were reported, further supports this finding. Only 10 days following the first outbreak, secondary cases started emerging. Although the new cases had no contact with the marketplace, they did have a history of social contact with the salesmen and people who had previously been there. The growing pile of confirmed cases from healthcare workers in Wuhan City is an strong indicator of human‐to‐human transmission in the case of SARS‐CoV‐2 (Sahin et al., [2020](#jcp29735-bib-0064){ref-type="ref"}).

Transmission of the virus from human to human occurs mostly with close contact. The short distance between individuals in close social contacts makes it possible for respiratory droplets of the infected person, released by coughing and sneezing, to reach other people in the proximity. This is similar to the transmission of Influenza and other respiratory infection. It still remains unclear if the virus can be contracted by touching surfaces, and then touching mouth, nose, or even eyes (WHO, [2020](#jcp29735-bib-0081){ref-type="ref"}). Apparently, COVID‐19 is considered most contagious when individuals infected with the virus is symptomatic. However, there have been cases who reportedly had contracted the disease from asymptomatic patients in the prodrome period of COVID‐19. Transmission of the novel Coronavirus has yet to be clarified by more investigations. (Rothe et al., [2020](#jcp29735-bib-0063){ref-type="ref"}).

4.1. Presumed asymptomatic carrier‐based transmission of COVID‐19 {#jcp29735-sec-0120}
-----------------------------------------------------------------

Investigation on a familial cluster of five patients concluded that SARS‐CoV‐2 might have actually been transmitted by an asymptomatic carrier in the family (Bai et al., [2020](#jcp29735-bib-0006){ref-type="ref"}). Surprisingly, the first reverse transcription polymerase chain reaction (RT‐PCR) test of the asymptomatic family member was reported negative; a noteworthy example of a false‐negative result. Unwanted false‐negative results are inevitably reported due to a number of factors, for example, quality of the test kit, sufficiency of the collected sample, or performance of the test by clinicians. To this date, RT‐PCR has widely been used as a reliable diagnostic method (Corman et al., [2020](#jcp29735-bib-0028){ref-type="ref"}). Thus, her second RT‐PCR result, reported positive, was unlikely to have been a false‐positive result; hence, it was accepted as the definite evidence that the suspected person had indeed been infected with SARS‐CoV‐2 (Bai et al., [2020](#jcp29735-bib-0006){ref-type="ref"}).

There was also another study that reported an asymptomatic young boy with COVID‐19 infection. However, CT scans obtained from the subject exhibited abnormalities, indicative of an on‐going pulmonary pathology (Chan et al., [2020](#jcp29735-bib-0010){ref-type="ref"}). If we presume that the findings regarding asymptomatic carrier‐based transmission of COVID‐19 can be replicated, this would prove COVID‐19 an overwhelmingly challenging issue to be controlled (Bai et al., [2020](#jcp29735-bib-0006){ref-type="ref"}). The incubation period for the asymptomatic patient in the case of familial cluster was 19 days. Despite being a long period, it still perfectly falls in the suggested incubation period of 0--24 days (Bai et al., [2020](#jcp29735-bib-0006){ref-type="ref"}; Guan et al., [2020](#jcp29735-bib-0035){ref-type="ref"}).

5. DIAGNOSIS {#jcp29735-sec-0130}
============

A proper diagnosis of COVID‐19 is made based on the following criteria, which have been recently suggested based on the initial investigations: (a) clinical signs and symptoms, (b) history of traveling or close contact with people suspected to be infected, (c) positive test result for the pathogen, and (d) pathologic findings on CT images. The key clinical features of COVID‐19, though nonspecific, include fever, dry cough, dyspnea, and pneumonia (Chen, Zhou, et al., [2020](#jcp29735-bib-0014){ref-type="ref"}; Huang et al., [2020](#jcp29735-bib-0040){ref-type="ref"}; Li, Guan, et al., [2020](#jcp29735-bib-0051){ref-type="ref"}; Wang, Hu, et al., [2020](#jcp29735-bib-0072){ref-type="ref"}). Rapid screening of patients with acute respiratory symptoms, initiation of an appropriate quarantine program, and development of therapeutic measures have been suggested as a top‐priority strategy to control the spread of COVID‐19 (Tian et al., [2020](#jcp29735-bib-0069){ref-type="ref"}; Wang, Kang, et al., [2020](#jcp29735-bib-0074){ref-type="ref"}). According to the data gathered by individual‐level surveillance, it is strongly recommended that the elderly and male patients should be diagnosed in a timely manner, as progression of the respiratory pathology to pneumonia might result in catastrophic outcomes (Jian‐ya, [2020](#jcp29735-bib-0041){ref-type="ref"}).

5.1. Clinical symptom spectrum {#jcp29735-sec-0140}
------------------------------

Understanding the otherwise nonspecific clinical signs and symptoms of COVID‐19 is a crucial step toward appropriate management of the disease. Patients mostly complain of fever, non‐productive cough, and body ache or extreme tiredness. In some cases, diarrhea and nausea precede fever by a few days, suggesting that fever might not be the initial manifestation of infection. A small number of patients reportedly had headache, or even developed hemoptysis (Guan et al., [2020](#jcp29735-bib-0035){ref-type="ref"}; Wang, Hu, et al., [2020](#jcp29735-bib-0072){ref-type="ref"}). Some patients remained asymptomatic, despite being tested positive for the disease (Chan et al., [2020](#jcp29735-bib-0010){ref-type="ref"}). According to several studies, infection with SARS‐CoV‐2 in the elderly, especially the male community, is more likely to result in severe alveolar damage and respiratory failure (Chen, Zhou, et al., [2020](#jcp29735-bib-0014){ref-type="ref"}). Occasionally, the disease may be demonstrated with a fulminant natural history, rapidly progressing to organ dysfunction, and even death in critical cases. Organ dysfunction includes conditions such as shock, ARDS, acute cardiac injury, and acute kidney injury (Huang et al., [2020](#jcp29735-bib-0040){ref-type="ref"}; Wang, Hu, et al., [2020](#jcp29735-bib-0072){ref-type="ref"}). From a laboratory point of view, lymphopenia, thrombocytopenia, impaired prothrombin time (PT), and elevated serum levels of CRP stand among the findings that can be reported for patients with COVID‐19 (Chen, Zhou, et al., [2020](#jcp29735-bib-0014){ref-type="ref"}; Guan et al., [2020](#jcp29735-bib-0035){ref-type="ref"}; Huang et al., [2020](#jcp29735-bib-0040){ref-type="ref"}; Wang, Hu, et al., [2020](#jcp29735-bib-0072){ref-type="ref"}). Overall, any patient with fever and acute respiratory symptoms, who is reported to have lymphopenia or leukopenia on lab examination, should be suspected. A history of travel to Wuhan or having close contact with local residents is a strong indicator for careful management of the patient (Zu et al., [2020](#jcp29735-bib-0098){ref-type="ref"}). Table [2](#jcp29735-tbl-0002){ref-type="table"} represents the criteria for diagnosis of COVID‐19 infected patients (Committee, [2020b](#jcp29735-bib-0027){ref-type="ref"}; Zu et al., [2020](#jcp29735-bib-0098){ref-type="ref"}; [WWW.ClinicalTrials.gov](http://WWW.ClinicalTrials.gov)).

###### 

Criteria for clinical severity of confirmed COVID‐19 pneumonia

  Patient    Clinical findings                                                             CT (imaging findings of pneumonia)                         Organ damage
  ---------- ----------------------------------------------------------------------------- ---------------------------------------------------------- -----------------------------------------
  Mild       Negative                                                                      None                                                       None
             No dyspnea, with or without cough, fever \<38°C (quelled without treatment)                                                              
             No history of chronic respiratory disease                                                                                                
  Moderate   dyspnea, with or without cough                                                Multifocal patchy GGOs with subpleural distribution        None
             SpO2 \>93% without oxygen inhalation                                                                                                     
  Severe     Fever                                                                         Diffuse heterogeneous consolidation with GGO,              None
             Muscle ache                                                                   Rapid progression (\>50%) on CT imaging within 24--48 hr   
             Headache                                                                                                                                 
             Confusion                                                                                                                                
             Respiratory distress:                                                                                                                    
             RR ≥ 30 times/min                                                                                                                        
             SpO2 \< 93% at rest                                                                                                                      
             PaO2/FiO2 ≤ 300 mmHg                                                                                                                     
  Critical   Shock                                                                                                                                    "Extra pulmonary" organ failure or MODS
             Respiratory failure                                                                                                                      
             need mechanical assistance                                                                                                               
             Intensive care unit is needed                                                                                                            

Abbreviations: FiO2, fraction of inspired oxygen; GGO, ground‐glass opacity; MODS, multiple organ dysfunction syndrome; PaO2, partial pressure of oxygen; RR, respiratory rate, SpO2, oxygen saturation.
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5.2. Epidemiological history {#jcp29735-sec-0150}
----------------------------

Shortly after the onset of the epidemic, The National Health Commission of China (Committee, [2020a](#jcp29735-bib-0026){ref-type="ref"}; Organization, [2020a](#jcp29735-bib-0077){ref-type="ref"}) initiated the Diagnosis and Treatment Program of COVID‐19‐associated pneumonia, following the guidelines provided by WHO on SARS and MERS (Azhar & EI‐Kafrawy, [2014](#jcp29735-bib-0005){ref-type="ref"}; Organization, [2017](#jcp29735-bib-0076){ref-type="ref"}, [2020b](#jcp29735-bib-0078){ref-type="ref"}).

According to the newly formulated criteria, a "suspected case" is defined as a patient with epidemiological history, that is traveling and contact, and two clinical findings pertinent to the disease. If, however, an epidemiological history is not confirmed, then the patient must present at least three clinical findings to be considered as a suspected case. Based on the Trial, Fifth Edition (Committee, [2020b](#jcp29735-bib-0027){ref-type="ref"}), pathologic findings indicative of viral pneumonia on chest CT scans provide enough evidence for clinical diagnosis of COVID‐19. Nonetheless, as of February 17, 2020, WHO does not approve of any diagnosis based solely on radiologic findings, without obtaining an RT‐PCR test from the patient (Organization, [2020c](#jcp29735-bib-0079){ref-type="ref"}). In the more recent revision of the Chinese Diagnosis and Treatment Program, 6th Edition, the term "clinical diagnosis" was removed and replaced with "etiological diagnosis" (Organization, [2020a](#jcp29735-bib-0077){ref-type="ref"}). According to the recent revision, it is imperative that an etiological diagnosis of COVID‐19 is made at first, which can then be complemented by a positive real‐time RT‐PCR assay for SARS‐CoV‐2, which is duly performed on the sputum or blood sample of the patient. After the final diagnosis is made, confirmed patients are categorized into mild, moderate, severe, and critical types, based on the severity of disease (Zu et al., [2020](#jcp29735-bib-0098){ref-type="ref"}).

5.3. COVID‐19 detection tests: Pathogenic laboratory testing, real‐time RT‐PCR, and sequencing of nucleic acid {#jcp29735-sec-0160}
--------------------------------------------------------------------------------------------------------------

Table [3](#jcp29735-tbl-0003){ref-type="table"} (Ai et al., [2020](#jcp29735-bib-0004){ref-type="ref"}; Bai et al., [2020](#jcp29735-bib-0006){ref-type="ref"}; Chen, Zhao, et al., [2020](#jcp29735-bib-0015){ref-type="ref"}; Shi et al., [2020](#jcp29735-bib-0066){ref-type="ref"}; Tian et al., [2020](#jcp29735-bib-0069){ref-type="ref"}; Wang, Kang, et al., [2020](#jcp29735-bib-0074){ref-type="ref"}; Wu & McGoogan, [2020](#jcp29735-bib-0084){ref-type="ref"}; Yan et al., [2020](#jcp29735-bib-0088){ref-type="ref"}; Yang et al., [2020](#jcp29735-bib-0089){ref-type="ref"}) and Table [4](#jcp29735-tbl-0004){ref-type="table"} represent 2020 studies on diagnosis of COVID‐19 infected patients and related clinical trials, respectively.

###### 

Studies for diagnosis, prognosis and therapy of COVID‐19 patients

<table><thead><tr class="header"><th>Study/region</th><th>Study type/medical team</th><th>Patient/median age/sex</th><th>Diagnostic test</th><th>Sample</th><th>Inclusion criteria/residency</th><th>Test results</th><th>Most common symptoms/chronic disease</th><th>Incubation period (day)</th><th>Case fatality rate</th><th>Diagnosis/prognosis/therapy</th></tr></thead><tbody><tr class="odd"><td>Wu et al. (<a href="#jcp29735-bib-0083" data-ref-type="ref">2020),</a> China</td><td>Retrospective study/Chinese Center for Disease Control and Prevention</td><td>72,314; subjects: confirmed cases 44,672 (62%), suspected cases 16,186 (22%), diagnosed cases 10,567 (15%), asymptomatic cases 889 (1%)/age <em>N</em> = 44,672: 80: 3% (1,408), 30–79: 87% (38,680), 20–29: 8% (3,619), 10–19: 1% (549), &lt;10: 1% (416)</td><td>PCR</td><td>Throat swab samples</td><td>Confirmed cases based on positive PCR, suspected cases based on symptoms and exposures only, clinically cases based on symptoms, exposures, and CT, asymptomatic cases diagnosis by positive PCR</td><td>Spectrum of disease: (<em>N</em> = 44,415); mild: 81% (36,160), severe: 14% (6,168), critical: 5% (2,087)</td><td>Cardiovascular disease: 10.5%, diabetes: 7.3%, chronic respiratory disease: 6.3%, hypertension: 6.0%, cancer: 5.6%</td><td>About a week</td><td>2.3% (1,023 of 44,672 confirmed cases), 14.8% aged &gt;80 years (208 of 1,408), 8.0% aged 70–79 years (312 of 3,918) 49.0% in critical cases (1,023 of 2,087)</td><td>Next step: to help “buy time” for more diagnostic and therapeutic research before COVID‐19 becomes too widespread</td></tr><tr class="even"><td>Tian et al. (<a href="#jcp29735-bib-0069" data-ref-type="ref">2020</a>), China</td><td>Retrospective study/Beijing Emergency Medical Service</td><td>262/47.5/48.5% male</td><td>Real‐time RT‐PCR</td><td>Respiratory specimens</td><td>COVID‐19 infected patients/residents of Beijing: 92 (73.3%), patients had been to Wuhan: 50 (26.0%), close contact with confirmed cases: 116 (60.4%), no contact history: 21 (10.9%)</td><td>Spectrum of disease: sever: 46 (17.6%); common: 216; (82.4%); mild: 192 (73.3%); nonpneumonia: 11 (4.2%); asymptomatic:13 (5.0%)</td><td>Fever (82.1%), cough (45.8%), fatigue (26.3%), dyspnea (6.9%), headache (6.5%)/pulmonary infection, chronic cardiovascular disease and heart failure: 1, pulmonary infection and multiple chronic diseases: 1</td><td>Incubation: 6.7 days, illness onset to visit hospital: 4.5 days</td><td>3 (0.9%)</td><td><p>Results: As of February 10, 45 (17.2%) patients have discharged</p><p>For COVID‐19 control: first step is prevent transmission at early stage, next steps is early isolation and quarantine of suspected subjects</p></td></tr><tr class="odd"><td>Wang et al. (<a href="#jcp29735-bib-0074" data-ref-type="ref">2020</a>), China</td><td>Retrospective cohort/Xi'an Jiaotong University First Affiliated Hospital, Nanchang University First Hospital and Xi'an No.8 Hospital of Xi'an Medical College</td><td>99</td><td>CT, artificial intelligence, inception migration‐learning model</td><td>–</td><td>Pathogen‐confirmed COVID‐19 patients</td><td>Spectrum of disease: typical viral pneumonia or negative group: 55, confirmed nucleic acid testing or positive group: 44. CT (453 CT images): negative: 258, positive: 195</td><td>Viral pneumonia symptoms</td><td>–</td><td>–</td><td><p>Screening:</p><p>The internal validation; accuracy: 82·9%, specificity: 80·5%, sensitivity: 84%</p><p>The external testing; accuracy: 73·1%, specificity: 67%, sensitivity: 74%</p><p>Algorithm prediction: a rate of 2 s per case on the graphic processing unit</p><p>Interpretation: the early diagnosis through fast, accurate, safe and noninvasive methods is crucial for control of virus</p></td></tr><tr class="even"><td>Yan et al. (<a href="#jcp29735-bib-0088" data-ref-type="ref">2020</a>), China</td><td>Retrospective study/Tongji Hospital</td><td>375, 58.83, 58.7% males</td><td>CT, machine learning model (a supervised XGBoost classifier)</td><td>–</td><td>Validated or suspected COVID‐19 patient/Wuhan residents (37.9%), familial cluster (6.4%), health workers (1.9%)</td><td>Spectrum of disease: critical patients: 46.1%, severe cases: RR ≥ 30bpm or SPO2 ≤93% on rest</td><td>Fever: 49.9%, cough: 13.9%, fatigue 3.7%, dyspnea 2.1%, shock: 2</td><td></td><td><p>174</p><p>16 + 1</p></td><td>Interpretation: the three indices‐based prognostic prediction model might predict themortality risk, recognition of critical cases, help to early identification, on time intervention, reducing mortality rate</td></tr><tr class="odd"><td>Shi et al. (<a href="#jcp29735-bib-0066" data-ref-type="ref">2020</a>), China</td><td>Retrospective/hospitals in Wuhan</td><td>81, 49–5, 42 (52%) men and 39 (48%) women</td><td>Next‐generation sequencing or RT‐PCR, serial chest CT</td><td>Throat swab specimens</td><td>Confirmed COVID‐19 pneumonia patients/direct exposure to Huanan seafood market: 31 (38%), health‐care workers: 15 (19%), familial clusters: 7 (9%), any obvious history of exposure: 28 (35%)</td><td><p>Spectrum of disease: mean number of involved lung segments: 10.5 (SD 6.4): group 1: subclinical patients (CT before symptom onset): 2.8 (3.3), group 2: ≤1 week after symptom onset/11.1 (5.4), group 3: &gt;1–2 weeks/13.0 (5.7), group 4: &gt;2–3 weeks/12.1 (5.9).</p><p>CT:</p><p>ALL:</p><p>bilateral abnormality: 64 [79%], peripheral 44 [54%], Ill‐defined 66 [81%], GGO: 53 [65%], mainly involving the right lower lobes: 225 [27%] of 849.</p><p>Group 1 (<em>n</em>=15): unilateral: 9 [60%]/multifocal 8 [53%]/GGO: 14 [93%]; Group 2 (<em>n</em> = 21): bilateral 19 [90%]/diffuse 11 [52%]/GGO predominance 17 [81%]; Group 3 (<em>n </em>= 30): GGO 17 [57%], consolidation/mixed patterns: 12 [40%]; Group 4 (<em>n</em>=15): consolidation/mixed patterns: 8 [53%].</p><p>Blood:</p><p>Group1: Lower CRP and AST</p></td><td><p>Fever: 59 [73%], dry cough: 48 [59%] nonspecific symptoms:</p><p>dizziness:</p><p>2 [2%], diarrhea:</p><p>3 [4%], vomiting:</p><p>4 [5%], headache:</p><p>5 [6%], generalised weakness:</p><p>7 [9%]/chronic pulmonary disease (tuberculosis): 1, T2D: 1, hypertension/cardiovascular/erebrovascular disease: 1</p></td><td>Symptom onset and discharge of 23–2 days</td><td>3 (4%)</td><td><p>By February 8, 2020, 62 (77%) patients discharged</p><p>Interpretation: COVID‐19 pneumonia include CT abnormalities that rapidly progress from focal unilateral to diffuse bilateral GGO coexisted with consolidations within 1–3 weeks (even in asymptomatic patients).</p><p>Early diagnosis through combined CT with clinical and laboratory findings</p></td></tr><tr class="even"><td>Bai et al. (<a href="#jcp29735-bib-0006" data-ref-type="ref">2020</a>), China</td><td>Case study/The Fifth People's Hospital of Anyang</td><td>6, Patient 1: 20‐year‐old woman, patients 2–6: four women 42–57 years old</td><td>CT, RT‐PCR</td><td>Nasopharyngeal swabs</td><td>Patient 1: met with Patients 2 and 3, and accompanied five relatives (Patients 2–6), Patients 2–6: no visited Wuhan or been in contact with any other people traveled to Wuhan</td><td><p>Spectrum of disease: severe pneumonia: 2, moderate: others. A familial cluster of five patients with respiratory symptoms, 1 asymptomatic family member.</p><p>Blood:</p><p>all symptomatic patients: increased CRP, reduced lymphocyte.</p><p>CT: multifocal GGO: in all symptomatic patients, subsegmental consolidation/fibrosis: 1.</p><p>Patient 1: normal CT, CRP and lymphocyte count, RT‐PCR: negative, positive, negative.</p><p>Patients 2–6:</p><p>COVID‐19 confirmed.</p><p>PCR: positive for patients 2–6 within 1 day</p></td><td>Fever: patients 2–6</td><td>19 days for patient 1</td><td>–</td><td>Transmission: COVID‐19 transmission could transmit by an asymptomatic carrier S</td></tr><tr class="odd"><td>Ai et al. (<a href="#jcp29735-bib-0004" data-ref-type="ref">2020</a>), China</td><td>Cohort/Tangji hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei</td><td>1,014/51 ± 15/46% man</td><td>Laboratory test, chest CT (7 day interval), RT‐PCR (Taq man one step): multiple assays (3 day interval)</td><td>Throat swab</td><td>Suspected of nCoV/China</td><td><p>Positive CT: 88% (888/1,014), positive RT‐PCR: 59% (601/1,014).</p><p>Sensitivity of CT based on positive RT‐PCR: 97% (95%CI, 95–98%, 580/601).</p><p>Negative RT‐PCR/positive CT: 75% (308/413).</p><p>Initial positive CT consistent with COVID‐19 before the initial positive RT‐PCR: 60–93%.</p><p>Improvement in follow‐up CT before the RT‐PCR turning negative: 42% (24/57), CT: GGO: 46% [409/888], consolidations: 50% [447/888], bilateral findings: 90% [801/888]</p></td><td>Fever, dry cough</td><td><p>Initial + to − PCR: 5.1 ± 1.5 days,</p><p>Initial − to + PCR: 6.9 ± 2.3 days</p></td><td>–</td><td>Diagnosis: chest CT, as a highly sensitive method, could be considered as a primary tool for infection diagnosis in epidemic areas</td></tr><tr class="even"><td>Chen et al. (<a href="#jcp29735-bib-0017" data-ref-type="ref">2020</a>), China</td><td>General Hospital of Central Theater Command, PLA</td><td>48/age; critically ill: 79.6 ± 12, sever: 63.9 ± 15, mild: 45.8 ± 14/31 males (77.1%) and 17 females (22.9%)</td><td>Real‐time RT‐PCR, CT, GLMs analysis</td><td>Serum, throat‐swab specimens</td><td>Laboratory confirmed cases</td><td><p>Spectrum of disease: mild: 21 (43.7%), severe 10 (20.8%), critically ill 17 (35.4%).</p><p>Blood: low/lower lymphocytes: severe and critically ill, higher neutrophils: critically ill, higher PCT: critically ill.</p><p>Parameters stand for the organ dysfunction; TnT, AST, ALT, CRE, and BUN: higher in critically ill patients.</p><p>PCR:</p><p>positive RNAaemia: (a) serum: 5 (10.4%) of critically ill, (b) throat‐swab: 48 positive.</p><p>IL‐6: value ≥100: 35.3% in critically ill, 10‐folds higher IL‐6 (cytokine storm): critically ill, RNAaemia positive: IL‐6 ≥100 (<em>R </em>= 0.902)</p></td><td><p>Mild: fever, respiratory symptoms</p><p>Severe: shortness of breath, RR ≥ 30 times/min, oxygen saturation (resting state) ≤93%, PaO2/FiO2 ≤300 mmHg</p><p>Critically ill: respiratory failure, shock, multiple organ failure/diabetes: 12 [25%], hypertension: 23 [49.7%], heart disease: 8 [16.7%], mixed fungal infection: 27.1%, bacterial infection: (2.1%)</p></td><td>–</td><td>3</td><td><p>Diagnosis; RNAaemia positive test confirmed critically ill patients</p><p>Prognosis: strong association between RNAaemia with cytokine storm can be applied to predict the poor prognosis</p><p>Therapeutic approach: in critically patients, IL‐6 should be considered as a therapeutic target</p></td></tr><tr class="odd"><td>Fan et al. (<a href="#jcp29735-bib-0032" data-ref-type="ref">2020</a>), China</td><td>Retrospective cohort study/three tertiary hospitals of Wenzhou</td><td>149/45.11 ± 13.35/81 (54.4%) males</td><td>Laboratory test, PCR, CT</td><td>Blood</td><td><p>RT‐PCR confirmed patients: Hubei travel/residence history: <em>N</em>=85,</p><p>contact with people of Hubei: <em>N</em>=49, no traceable exposure history: <em>N</em>=15</p></td><td><p>Blood:</p><p>decreased oxygen saturation: 14(9.4%), leukopenia: 33 (24.2%), lymphopenia: 53 (35.6%), low platelets: 20 (13.4%), elevated CRP: 82 (55.0%), ALT/AST/CK and D‐dimer: less common.</p><p>CT: most involved lung segments: 6 and, GGO: 287 segments, mixed opacity: 637 segments, consolidation: 170 segments, lesions: more in the peripheral lung with a patchy form, normal CT on admission: <em>N</em>=17, negative CT: <em>N</em>=12, no significant difference between patients with or without exposure history</p></td><td><p>Fever:</p><p>114/149, 76.5%,</p><p>Cough: 87/149, 58.4%,</p><p>Expectoration:</p><p>4 8/149, 32.2%, mild infection/cerebrovascular or digestive diseases:</p><p>52 (34.9%)</p></td><td>Negative CT: 10 days, 6.8 (5.0) days</td><td>0 (0.0%)</td><td>Diagnosis: a normal CT cannot exclude the diagnosis of COVID‐19</td></tr><tr class="even"><td>Fan et al. (<a href="#jcp29735-bib-0032" data-ref-type="ref">2020</a>), China</td><td>Retrospective, case series/Chongqing University Three Gorges Hospital</td><td>51/45/32 (62.7%) men</td><td>Laboratory test, CT</td><td>Blood</td><td><p>Confirmed COVID‐19: patients had been to Wuhan:</p><p>43 (84.3%), contact history of COVID‐19 patients: 4 (7.7%), no clear contact history:4 (7.7%)</p></td><td><p>Spectrum of disease:</p><p>nonsevere patients: <em>n</em> = 44, severe patients: 7 (13.7%)</p><p>Blood: lymphopenia: 26 (51.0%), elevated CRP: 32 (62.7%).</p><p>CT:</p><p>GGO: 41 [80.4%], local consolidation of pneumonia:</p><p>17 [33.3%], pleural thickening: 20 (39.2%), small amount of pleural effusion:</p><p>7 (13.7%), streak shadow of lung: 8 (15.7%), multiple solid nodular shadow: 4 (7.8%), air bronchogram: 2 (3.9%), single lobe lesions: 2 (3.9%), multiple lobe lesions: 49 (96.1%)</p></td><td><p>Fever:</p><p>43 [84.3%], cough:</p><p>38 [74.5%], dry cough with expectoration:</p><p>16 (31.4%), fatigue: 22 [43.1%], asthenia: 22 (43.1%), dyspnea: 11/DM: 4 [57.1%]</p></td><td>2–5 days</td><td>1</td><td><p>Therapy:</p><p>TCM decoction: 28 [54.9%], aerosol inhalation of recombinant human</p><p>Interferon a‐1b: 51 (100%), Lopinavir/Ritonavir: 51 [100%], <em>Bacillus licheniformis</em> capsules: 44 [86.3%], glucocorticoid treatment: 10 (19.6%)</p><p>Older patients with server COVID‐19 (<em>N </em>= 7)</p><p>Antibiotic treatment: 7 [100%], nutritional diet: 6 [85.7%), human albumin infusion: 4 (57.1%), immunoglobulin treatment: 4 (57.1%), mechanical ventilation: 6 [85.7%]</p><p>Results and interpretation: discharged 50 patients after 12 days, without the common clinical symptoms, with the significant increased lymphocyte (<em>p</em> = .008) and significant decreased CRP significantly (<em>p</em> &lt; .001)</p></td></tr><tr class="odd"><td>Fan et al. (<a href="#jcp29735-bib-0032" data-ref-type="ref">2020</a>), China</td><td>Retrospective/Shanghai Public Health Clinical Center</td><td>148/50.5/49.3% females and 50.7% males</td><td>Laboratory test, RT‐PCR and CT scanning</td><td>Sera</td><td>Confirmed SARS‐CoV‐2‐infected patients/a history of related epidemiology</td><td><p>Blood:</p><p>elevated LDH, AST, ALT, GGT, TB, ALP:</p><p>35.1%, 21.6%, 18.2%, 17.6%, 6.1%, 4.1% in all patients; lower CD4+ and CD8+ T cells: (62.67%)/(56.1%) patients with abnormal liver function received more treatment compared with normal liver function (25%) (<em>p</em> = .009)</p></td><td><p>Fever: (70.1%), cough: (45.3%), expectoration at admission:</p><p>(26.7%),</p><p>Abnormal liver functions at admission: 75 patients (50.7%) with moderate‐high degree fever (44%) in males,/chronic hepatitis B or C: <em>N</em> = 8</p></td><td>5 days (3–7)</td><td>1</td><td><p>Therapy:</p><p>Antibiotics (Levofloxacin, Meropenem, Moxifloxacin, Cephalosporin), interferon, antiviral drugs (Arbidol, Lopinavir/ritonavir, Dnrunavir)</p><p>Results and interpretation:</p><p>all patients discharged from the hospital.</p><p>Lopinavir/Ritonavir treatment can significantly alleviate the SARS‐CoV‐2‐induced liver function damage</p></td></tr><tr class="even"><td>Chen et al. (<a href="#jcp29735-bib-0017" data-ref-type="ref">2020</a>) China</td><td>Retrospective/Zhongnan Hospital of Wuhan University, Wuhan</td><td>9/26–34/female</td><td>Clinical records, laboratory results, CT scans</td><td>Amniotic fluid, cord blood, and neonatal throat swab, breastmilk samples</td><td>Pregnant women with laboratory‐confirmed COVID‐19 pneumonia and caesarean section in their third trimester/a history of epidemiological exposure to COVID‐19</td><td><p>Blood:</p><p>lymphopenia: <em>N</em> = 5, elevated CRP: <em>N </em>= 6, increased ALT and AST: <em>N </em>= 3, normal WBC count: <em>N </em>= 7, lower WBC: <em>N </em>= 1.</p><p>Nine mothers: none developed severe COVID‐19 pneumonia or dying as of Feb4.</p><p>Six mothers:</p><p>amniotic fluid, cord blood, neonatal throat swab, and breastmilk: negative for COVID‐19.</p><p>Nine livebirths:</p><p>with 1‐min Apgar score of 8–9 and a 5‐min Apgar score of 9–10, No neonatal asphyxia.</p><p>CT:</p><p>multiple patchy ground‐glass shadows: <em>N</em>=8</p></td><td><p>Fever: <em>N </em>= 7, cough <em>N </em>= 4, myalgia <em>N </em>= 3, sore throat: <em>N</em> = 2, malaise: <em>N</em> = 2, fetal distress:</p><p><em>N</em> = 2/gestational hypertension:</p><p><em>N </em>= 1, pre‐eclampsia: <em>N</em> = 1, influenza virus infection: <em>N </em>= 1</p></td><td>Short</td><td>None</td><td><p>Therapy: oxygen support (nasal cannula) and empirical antibiotic treatment: <em>N</em> = 9, antiviral therapy: <em>N</em> = 6</p><p>Interpretation: no evidence for intrauterine infection caused by vertical transmission in late pregnancy</p></td></tr><tr class="odd"><td>Lim et al. (<a href="#jcp29735-bib-0053" data-ref-type="ref">2020</a>), Korea</td><td>Public health center, Myongji Hospital</td><td>1/54/male</td><td>PCR, CT</td><td>Throat swab, sputum</td><td><p>A Korean man living in Wuhan China/Virus transmission;</p><p>from index patient Patient A to Patients B, C, D@@</p></td><td><p>Spectrum of disease: mild respiratory symptoms.</p><p>CT:</p><p>small consolidation in right upper lobe, GGO in both lower lobes</p></td><td>Chills, muscle pain</td><td>5–7 days</td><td>–</td><td><p>Therapy:</p><p>Lopinavir/Ritonavir</p><p>Results and interpretation:</p><p>significant decrease in β‐coronavirus viral loads due to the natural course of the healing process rather than administration of Lopinavir/Ritonavir, or both</p></td></tr><tr class="even"><td>Wu et al. (<a href="#jcp29735-bib-0083" data-ref-type="ref">2020</a>), China</td><td>Retrospective/three Grade IIIA hospitals of Jiangsu</td><td>80/46.1/41 female (51.25%)</td><td>Laboratory testing, real time RT‐PCR, CT</td><td>Throat swab and/or nose swab, blood</td><td>Confirmed COVID‐19 patients/with a history of epidemic in Wuhan and without contact with the seafood market</td><td><p>Spectrum of disease:</p><p>mild: 28 (35.00%), moderate: 49 (61.25%), severe: 3 (3.75%), critically ill: none</p><p>Laboratory:</p><p>lower WBC: 36 (45.00%), lymphocytopenia: 26 (32.50%), lower platelets: 11 (13.75%), high CRP: 62 (77.50%), high ESR: 59 (73.75%), elevated PCT: 1 (1.25%).</p><p>Liver function:</p><p>increased ALT/AST: 3 (3.75%), lower albumin: 2 (2.50%).</p><p>Abnormal myocardial enzyme spectrum and increase of CK: 18 (22.50%).</p><p>Increased LDH: 17 (21.25%).</p><p>Renal function damage: 2 (2.50%).</p><p>Serious renal function damage: 1.</p><p>Hyperglycemia: 19 (23.17%).</p><p>Increased D‐dimer: 3 (3.75%).</p><p>9 kinds of respiratory pathogens and influenza A/B nucleic acids: all patients.</p><p>CT: abnormal: 55 (68.75%), bilateral pneumonia: 36 (45.00%), unilateral pneumonia: 19 (23.75%), normal: 25 (31.25%).</p><p>Organ damage: acute respiratory injury: 10 (12.50%), renal injury: 2 (2.50%)</p></td><td><p>Fever:</p><p>63 (78.75%), cough: 51 (63.75%), shortness of breath: 30 (37.50%), muscle ache: 18 (22.50%), headache: 13 (16.25%) liver dysfunction: 3 (3.75%)/cardiovascular/cerebrovascular, endocrine, digestive, respiratory, malignancies and nervous system diseases: 38 (47.50%)</p></td><td>8.0</td><td>Not now</td><td><p>Therapy:</p><p>all patients:</p><p>single antibiotic mainly Moxifloxacin and Ribavirin antiviral therapy, 12 (14.63%) patients:</p><p>methylprednisolone sodium succinate or methylprednisolone, 35 (43.75%) patients:</p><p>noninvasive ventilator, 1 patient: hemodialysis, 3 patients: TCM</p><p>Interpretation: 21 cases discharged from the hospital: With no obvious gender susceptivity, lower proportion of liver dysfunction, abnormal CT and higher frequency nucleic acid detection</p></td></tr><tr class="odd"><td>Li et al. (<a href="#jcp29735-bib-0050" data-ref-type="ref">2020</a>), China</td><td>Retrospective study/hospital in Wenzhou</td><td>175/46/92 women, 83/men</td><td>Real‐time PCR, CT</td><td>Respiratory tract samples or blood samples</td><td>Confirmed COVID‐19/a history of exposure to the epidemic area: 57 (33%) patients</td><td><p>Spectrum of disease:</p><p>COVID‐19:</p><p>mild: mild clinical manifestations, no pneumonia; moderate: respiratory symptoms, mild pneumonia, severe (37): pneumonia, ARDS with RR &gt;30 times/min, oxygen saturation &lt;93%; critical (3): pneumonia, shock, respiratory failure, and failures in other organs, nearly all patients: GGO</p><p>K<sup>+</sup>:</p><p>severe hypokalemia: 39 (higher body temperature, higher heart rate and RR, higher prevalence of dyspnea or tachypnea (<em>p</em> &lt; .05)), hypokalemia 69, normokalemia patients 67.</p><p>Correlations: severity of hypokalemia with body temperature, CK, CK‐MB, LDH, and CRP (<em>p </em>&lt; .01), 93% of severe/critically ill patients showed hypokalemia</p></td><td>Cough, fever, pneumonia/hypertension: 28, diabetes: 12, other conditions:31</td><td>6</td><td>–</td><td><p>Therapy:</p><p>1 severe hypokalemia patients;</p><p>3 g/day K<sup>+</sup>, 34 (<em>SD</em> = 4) g potassium during hospital stay</p><p>Good response of patients to K+ supplements when they inclined to recovery</p><p>Interpretation: hypokalemia is prevailing in COVID‐19 patients</p></td></tr><tr class="even"><td>Lan et al. (<a href="#jcp29735-bib-0049" data-ref-type="ref">2020</a>), China</td><td>Case study/Zhongnan Hospital of Wuhan University, Wuhan</td><td>4, 30–36 years, 2 male</td><td>RT‐PCR, thin‐section CT</td><td>Throat swabs</td><td>Medical personnel quarantined at home with COVID‐19</td><td><p>Spectrum of disease: mild to moderate</p><p>Results: (at admission); PCR positive: for all CT positive: for all GGO, or mixed GGO/consolidation</p><p>(after therapy); 2 consecutive negative RT‐PCR: all (after discharge); repeated RT‐PCR 5–13 days later: all positive</p></td><td>Fever:3, cough: 3, both: 3</td><td>Symptom onset to recovery: 12–32 days</td><td>–</td><td><p>Therapy: antiviral treatment (75 mg of oseltamivir every 12 hr)</p><p>Resolved clinical symptoms and CT abnormalities: 3</p><p>Delicate patches of GGO: 1</p><p>Interpretation: possibility of at least a proportion of recovered patients act as virus carriers</p></td></tr><tr class="odd"><td>Li et al. (<a href="#jcp29735-bib-0051" data-ref-type="ref">2020</a>), China</td><td>Retrospective study/Sino‐French New Town area Tongji Hospital</td><td>47, 62, 28 (59.6%) men</td><td>Real‐time RT‐PCR</td><td>Throat‐swab specimens, sputum or endotracheal aspirates</td><td>Patients with severe COVID‐19</td><td><p>Spectrum of disease: severe: 41 critical: 5(17.9%) men and 1 (5.3%) women</p><p>Common: oxygen saturation &lt;93% after routine</p><p>Nasal oxygen supply: 3 men/1 woman</p><p>Blood: PCT: higher in men, N‐terminal‐pro brain natriuretic peptide: Higher in 16(57.1%) men/5 (26.3%) women,</p><p>Positive influenza A antibody: 5 men (17.9%)</p></td><td><p>Fever: 34 [72.3%], cough: 36 [76.6%], myalgia: 5 [10.6%], fatigue: 7 [14.9%]/comorbidities: 30 (63.8%):</p><p>COPD, hypertension/CVD lower in men</p></td><td>–</td><td>3.6% in men and 0 in women</td><td><p>Therapy:</p><p>antibiotics applied more in the men than the women</p><p>Results and interpretation: 4 (21.1%) women/1 man (3.6%) discharged.</p><p>Possibility of sex differences in severe COVID‐19 patients, Men with more complicated clinical condition and worse outcomes</p></td></tr><tr class="even"><td>Han et al. (<a href="#jcp29735-bib-0037" data-ref-type="ref">2020</a>)</td><td>Case study/People's Hospital in Wuwei</td><td>A 47‐year‐old man/smoking for 20 years/no alcohol abuse</td><td>RT‐PCR, CT</td><td>Nasopharyngeal swab specimens</td><td>Confirmed SARS‐CoV‐2/returned to Wuwei city on January 18 from Wuhan city by car</td><td><p>Blood:</p><p>decreased lymphocytes, increased CRP, slightly elevated fibrinogen, neutrophil, LDH, and fibrinogen</p><p>PCR: positive for expression of RdRPN, N and E genes</p><p>CT: multiple patchy high‐density shadows scattered mainly in the border regions of lungs, solid changes, GGO changes, slightly thickened pleura</p></td><td>Fever, cough productive of white phlegm, bosom frowsty, stuffy/runny noses, vertigo, fatigue, chest tightness, nausea, expiratory dyspnea, poor diet, lethargy/hypertension grade 2 and T2D</td><td>–</td><td>–</td><td><p>Therapy:</p><p>combination therapy including:</p><p>Lopinavir/Ritonavir (800/200 mg daily), methylprednisolone (40 mg daily), recombinant human interferon α‐2b (10 million IU daily), ambroxol hydrochloride (60 mg daily) moxifloxacin hydrochloride (0.4 g daily), high flow humidification oxygen inhalation therapy, treatment of blood glucose, blood pressure, and rehydration therapy</p><p>Results interpretation: the persistent negative results of SARS‐CoV‐2 on days 6 and 7, normal TLC, lung lesions partially absorbed, The patient discharged. Laboratory tests like TLC are necessary, CT combined with RT‐PCR is helpful, Lopinavir/Ritonavir are effective after failure of methylprednisolone/interferon alfa‐2b</p></td></tr><tr class="odd"><td>Liu et al. (<a href="#jcp29735-bib-0054" data-ref-type="ref">2020</a>), China</td><td>Retrospective cohort and case study/Zhongnan Hospital of Wuhan University Dawu County People's Hospital</td><td><p>124 patients, 22 patients:</p><p>12 therapy (mean age 53), 10 control (mean age 58)</p></td><td>CT, PCR</td><td>Serum</td><td>124 confirmed COVID‐19 cases, 12 HCOV infected patients</td><td><p>Blood: (Study 1) decreased platelet: 25 (20.2%), prolonged PT: 77 (62.1%), increased FIB: 27 (21.8%), and increased D‐dimer: 26 (21.0%)</p><p>Spectrum of disease: (study 2) severe cases: 6 mild cases: 4 critically ill: 2</p><p>CT: (study 2) Bilateral pneumonia: all</p></td><td><p>Study 1: hypercoagulability</p><p>Study 2: cough: all shortness of breath: most of them, nausea and vomiting: 60.0%/DM, cardiovascular and cerebrovascular diseases: 4 patients from the DIP, 5 patients control group</p></td><td>–</td><td>1</td><td><p>Therapy: Dipyridamole (150 mg in three separate doses for 7 consecutive days), antiviral (ribavirin, 0.5 g, Q12hr), corticoid (methylprednisolone sodium succinate, 40 mg, qd), oxygen therapy, nutritional support</p><p>Results and interpretation: significant increase in platelet/lymphocyte, significant decrease in D‐dimer levels</p><p>Discharged patients: 50% of severe cases and all 4 mild cases.</p><p>Dipyridamole adjunctive therapy could significantly reduce viral replication, inhibits hypercoagulability and improves immune recovery</p></td></tr></tbody></table>

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; ARDS, acute respiratory distress syndrome; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CK, creatine kinase; CK‐MB, creatine kinase myocardial band; COPD, chronic obstructive pulmonary disease; CRE, serum creatinine; CRP, C‐reactive protein; CT, computed tomography; CVD, cardiovascular disease; DM, diabetes mellitus; DM, diabetes mellitus; ESR, erythrocyte sedimentation rate; FIB, fibrinogen; FiO2, fraction of inspired oxygen; GGO, ground‐glass opacity; GGT, γ‐glutamyltransferase; GLM, Generalized Linear Model; LDH, lactate dehydrogenase; nCoV, novel coronavirus; PaO2, partial pressure of oxygen; PCT, procalcitonin; PT, prothrombin time; RNAaemia, SARS‐CoV‐2 nucleic acid; RR, respiratory rate; RT‐PCR, reverse transcriptase polymerase chain reaction; SpO2, oxygen saturation; T2D, type 2 diabetes; TB, total bilirubin; TCM, traditional Chinese medicine; TCM, traditional Chinese medicine; TLC, total lymphocyte count; TnT, troponin T; WBC, white blood cell.
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###### 

Clinical trials for COVID‐19 or SARS‐nCoV2

+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Study title                                                                                                                                                                                           | Interventions                                                                                                                                         | Location/condition                                               | Subjects, sex, age                                               | Primary purpose                      | Arms                                                                                                                                                                                                                                                                                                                                                                                                      | Phase                                      | Measure outcome/time frame                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Code/status/date                                       |
+=======================================================================================================================================================================================================+=======================================================================================================================================================+==================================================================+==================================================================+======================================+===========================================================================================================================================================================================================================================================================================================================================================================================================+============================================+================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================+========================================================+
| The efficacy and safety of huaier in the adjuvant treatment of COVID‐19                                                                                                                               | Drug: Huaier Granule                                                                                                                                  | COVID‐19                                                         | 550, all, 18--75                                                 | Treatment                            | Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)                                                                                                                                                                                                                                                                                                      | II, III                                    | Primary (up to 28 days): all cause mortality                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | NCT04291053/Not yet recruiting, Apr1‐Sep1 2020         |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Control group: standard therapy                                                                                                                                                                                                                                                                                                                                                                           |                                            | Secondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Clinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19                                                                                                                | Drug: TCM prescriptions                                                                                                                               | China/COVID‐19                                                   | 340, all, 18--75                                                 | Treatment                            | Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)                                                                                                                                                                                                       | Not applicable                             | Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | NCT04306497/Recruiting, Mar2‐May 2020                  |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Control group: western medicine cohort (routine treatment + one or both of the following antiviral drugs)                                                                                                                                                                                                                                                                                                 |                                            | Secondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | Other outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Recombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19                                                                                                  | Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2)                                                                                      | China/COVID‐19                                                   | 24, all, 18--80                                                  | Treatment                            | Experimental group: 0.4 mg/kg rhACE2 IV BID for 7 days and standard of care                                                                                                                                                                                                                                                                                                                               | Not applicable                             | Primary (14 days): time course of body temperature, viral load over time                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | NCT04287686/Withdraw, Feb‐Apr 2020                     |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Control group: standard of care                                                                                                                                                                                                                                                                                                                                                                           |                                            | Secondary (14 days): P/F ratio over time, sequential organ failure assessment score over time, Pulmonary Severity Index, image examination of chest over time, proportion of subjects who progressed to critical illness or death, Time from first dose to conversion to normal or mild pneumonia, T‐lymphocyte counts over time, C‐reactive protein levels over time, angiotensin II (Ang II) changes over time, angiotensin 1--7 (Ang 1--7) changes over time, angiotensin 1--5 (Ang 1--5) changes over time, renin changes over time, aldosterone changes over time, angiotensin‐converting enzyme changes over time, angiotensin‐converting enzyme 2 (ACE2) changes over time, IL‐6 changes over time, IL‐8 changes over time, soluble tumor necrosis factor receptor type II (sTNFrII) changes over time, Plasminogen activator inhibitor type‐1 changes over time, Von willebrand factor changes over time, tumor necrosis factor‐α changes over time, soluble receptor for advanced glycation end products (sRAGE) changes over time, surfactant protein‐D changes over time, angiopoietin‐2 changes over time, frequency of adverse events and severe adverse events                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| The COVID‐19 mobile health study (CMHS)                                                                                                                                                               | nCapp, a cell phone‐based autodiagnosis system                                                                                                        | China/COVID‐19                                                   | 450, all, 18--90                                                 | Diagnosis                            | Training: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to autodiagnosis of the risk of COVID‐19                                                                                                                                                                                                                                            | --                                         | Primary (1 day): accuracy of nCapp COVID‐19 risk diagnostic model                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | NCT04275947/Recruiting, Feb 14‐May 31 2020             |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Validation: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to auto‐diagnosis of the risk of COVID‐19                                                                                                                                                                                                                                         |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| A Pilot Study of Sildenafil in COVID‐19                                                                                                                                                               | Drug: Sildenafil citrate tablets (G1)                                                                                                                 | China/COVID‐19                                                   | 10, all, 18 years and older                                      | Treatment                            | Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days                                                                                                                                                                                                                                                                                                                                       | Not applicable                             | Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | NCT04304313/Recruiting, Feb 9‐Nov 9 2020               |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | Secondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Critically Ill patients with COVID‐19 in Hong Kong: a multicentre observational cohort study                                                                                                          | --                                                                                                                                                    | Hong Kong/COVID‐19                                               | 8                                                                | descriptive                          | A case series of 41 hospitalized patients with confirmed infection                                                                                                                                                                                                                                                                                                                                        | −                                          | Primary (28 days): 28 day mortality                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | NCT04285801/Completed, Feb 14‐Feb 25 2020              |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | 30% required critical care admission: developed severe respiratory failure, 10% required mechanical ventilation, 5% needed extracorporeal membrane oxygenation support mortality rate: 15%                                                                                                                                                                                                                |                                            | Secondary (28 days): vasopressor days, days on mechanical ventilation, sequential organ function assessment score, ECMO use, percentage nitric oxide use, percentage free from oxygen supplement                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Treatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic                                                                                                       | Drug: antiviral treatment and prophylaxis, Standard Public Health measures                                                                            | COVID‐19                                                         | 3,040, All, 18 Years and older                                   | Treatment                            | Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures                     | III                                        | Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | NCT04304053/Not yet recruiting, Mar15‐Jul15 2020       |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Active comparator: standard public health measures                                                                                                                                                                                                                                                                                                                                                        |                                            | Secondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Comparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19)                                                                                          | Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate                                                                                           | Korea/COVID‐19                                                   | 150, all, 16 years to 99 years                                   | Treatment                            | Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7--10 days                                                                                                                                                                                                                                                                                                            | II                                         | Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | NCT04307693/Recruiting, Mar11‐May 2020                 |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Active comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7--10 days                                                                                                                                                                                                                                                                                                               |                                            | Secondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | No intervention: control, no lopinavir/ritonavir and hydroxychloroquine                                                                                                                                                                                                                                                                                                                                   |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19)                                                               | Drug: remdesivir, standard of care                                                                                                                    | United States, Hong Kong/COVID‐19                                | 400, all, 18 years and older                                     | Treatment                            | Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5                                                                                                                                                                                                                       | III                                        | Primary: proportion of participants with normalization of fever and oxygen saturation through day 14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | NCT04292899/Recruiting, Mar6‐May 2020                  |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10                                                                                                                                                                                                            |                                            | Secondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment                      | Drug: remdesivir, standard of care                                                                                                                    | United States, Hong Kong,                                        | 600, all, 18 years and older                                     | Treatment                            | Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.                                                                                                                                                                                                                            | III                                        | Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | NCT04292730/Recruiting, Mar‐May 2020                   |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Active comparator: continued standard of care therapy                                                                                                                                                                                                                                                                                                                                                     |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Bevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT                                                                                                                                | Drug: bevacizumab                                                                                                                                     | China/COVID‐19 Pneumonia                                         | 118, all, 18--80                                                 | Treatment                            | Experimental; bevacizumab, group:                                                                                                                                                                                                                                                                                                                                                                         | Not applicable                             | Primary: proportion of patients whose oxygenation index increased by 100 mmHg on the 7th day after admission                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | NCT04305106/Not yet recruiting, Mar12‐May31 2020       |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | bevacizumab 500 mg + 0.9% NaCl 100 ml, intravenous drip                                                                                                                                                                                                                                                                                                                                                   |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | No intervention: control group                                                                                                                                                                                                                                                                                                                                                                            |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| The efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID‐19) pneumonia                                                                                     | Drug: thalidomide, placebo                                                                                                                            | COVID‐19 thalidomide                                             | 100, all, 18 years and older                                     | Treatment                            | Placebo comparator: control group: placebo 100 mg, po, qn, for 14 days                                                                                                                                                                                                                                                                                                                                    | II                                         | Primary (up to 28 days): time to clinical recovery time to clinical recovery (up to 28 days)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | NCT04273529/Not yet recruiting, Feb20‐Jun30 2020       |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Experimental: thalidomide group 100 mg, po, qn, for 14 days. Other name: fanyingting                                                                                                                                                                                                                                                                                                                      |                                            | Secondary (up to 28 days): all cause mortality (up to 28 days), frequency of respiratory progression, Time to defervescence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | Others(up to 28 days): time to cough reported as mild or absent, respiratory improvement time, frequency of requirement for supplemental oxygen or noninvasive ventilation, Time to 2019‐nCoV RT‐PCR negative in upper respiratory tract specimen, change (reduction) in 2019‐nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve, frequency of requirement for mechanical ventilation, frequency of serious adverse events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10, MCP1, MIP1α and other cytokine expression levels before and after treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| The efficacy and safety of thalidomide combined with low‐dose hormones in the treatment of Severe COVID‐19                                                                                            | Placebo, drug: thalidomide                                                                                                                            | COVID‐19 thalidomide                                             | 40, all, 18 years and older                                      | Treatment                            | Placebo comparator: control group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. placebo: 100 mg/d, qn, for 14 days                                                                                                | II                                         | Primary (up to 28 days): time to clinical improvement                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | NCT04273581/Not yet recruiting, Feb18‐May30 2020       |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Experimental: thalidomide group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. thalidomide: 100 mg/d qn for 14 days                                                                                                |                                            | Secondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for 24 hr, all cause mortality, duration (days) of mechanical ventilation, duration (days) of extracorporeal membrane oxygenation, duration (days) of supplemental oxygenation, length of hospital stay (days), time to 2019‐nCoV RT‐PCR, change (reduction) in 2019‐nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve, frequency of serious adverse drug events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10\#MCP1, MIP1α, and other cytokine expression levels before and after treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Tetrandrine tablets used in the treatment of COVID‐19                                                                                                                                                 | Drug: tetrandrine                                                                                                                                     | China/COVID‐19                                                   | 60, all, 18--75                                                  | Treatment                            | Experimental: tetrandrine cohort after the subjects were enrolled, they were given "Tetrandrine 60 mg QD" for a course of 1 week (take 6 days, stop using for 1 day)                                                                                                                                                                                                                                      | IV                                         | Primary (12 weeks): survival rate secondary (2 weeks): body temperature                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | NCT04308317/Enrolling by invitation, Mar5‐May1 2020    |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | No intervention: control cohort treatment according to standard protocols without intervention                                                                                                                                                                                                                                                                                                            |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Fingolimod in COVID‐19                                                                                                                                                                                | Biological: UC‐MSCs, other: placebo                                                                                                                   | China/COVID‐19                                                   | 30, all, 18--80                                                  | Treatment                            | Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days                                                                                                                                                                                                                                                | II                                         | Primary (5 day after treatment): the change of pneumonia severity on X‐ray images                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | NCT04280588/Recruiting, Feb22‐Jul1 2020                |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | No Intervention: control group                                                                                                                                                                                                                                                                                                                                                                            |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Therapy for pneumonia patients infected by 2019 novel coronavirus                                                                                                                                     | Biological: UC‐MSCs, other: placebo                                                                                                                   | China/COVID‐19                                                   | 48, all, 18--75                                                  | Treatment                            | Experimental: UC‐MSCs treatment group, participants will receive conventional treatment plus four times of 0.5\*10E6 UC‐MSCs/kg body weight intravenously at Day1, Day3, Day5, Day7)                                                                                                                                                                                                                      | Not applicable                             | Primary (at baseline, Day 1, Weeks 1, 2, 4, 8): size of lesion area by chest imaging, blood oxygen saturation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | NCT04293692/Recruiting, Feb24‐Feb1 2020--2021          |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Placebo comparator: control group, participants will receive conventional treatment plus 4 times of placebo intravenously at Day1, Day3, Day5, Day7                                                                                                                                                                                                                                                       |                                            | Secondary (at baseline, Day 1, Weeks 1, 2, 4, 8): rate of mortality within 28‐days, sequential organ failure assessment, side effects in the UC‐MSCs treatment group, Electrocardiogram, the changes of ST‐T interval mostly, Concentration of C‐reactive protein C‐reactive protein, immunoglobulin, CD4 + and CD8 + T cells count, Concentration of the blood cytokine (IL‐1β, IL‐6, IL‐8,IL‐10,TNF‐α), Concentration of the myocardial enzymes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| The Use PUL‐042 inhalation solution to prevent COVID‐19 in adults exposed to SARS‐CoV‐2                                                                                                               | Drug: PUL‐042 inhalation solution, drug: placebo                                                                                                      | COVID‐19                                                         | 200, all, 18 years and older                                     | Treatment                            | Experimental: PUL‐042 inhalation solution, PUL‐042 inhalation solution (20.3 µg Pam2: 29.8 µg ODN/mL) given by nebulization on study days 1,3, 6, and 10                                                                                                                                                                                                                                                  | II                                         | Primary (14 days): Prevention of COVID‐19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | NCT04313023/Not yet recruiting, Apr‐Oct 2020           |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Placebo comparator: sterile normal saline for inhalation, sterile normal saline for inhalation given by nebulization on study days 1, 3, 6, and 10                                                                                                                                                                                                                                                        |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Treatment of COVID‐19 patients using Wharton\'s jelly‐mesenchymal stem cells                                                                                                                          | Biological: WJ‐MSCs                                                                                                                                   | Arabia Amman, Jordan/use of stem cells for COVID‐19 treatment    | 5, all, 18 years and older                                       | Treatment                            | Experimental: WJ‐MSCs WJ‐MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, mycoplasma, and cultured to enrich for MSCs.                                                                                                                                                                                                                                              | I                                          | Primary (3 weeks): Clinical outcome, CT Scan, RT‐PCR results                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | NCT04313322/Recruiting, Mar16‐Sep30 2020               |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | WJ‐MSCs will be counted and suspended in 25 ml of saline solution containing 0.5% human serum albumin, and will be given to patient intravenously                                                                                                                                                                                                                                                         |                                            | Secondary (8 weeks): RT‐PCR results                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Myocardial damage in COVID‐19                                                                                                                                                                         | Non                                                                                                                                                   | China/COVID‐19 cardiovascular diseases                           | 500, all, 18 years and older                                     | Prognostic                           | Discharged group (no intervention) the individual which is defined as patient discharged from hospital                                                                                                                                                                                                                                                                                                    | --                                         | Primary (75 days): the myocardial injury incidence, the risk factors analysis for the death                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | NCT04312464/Enrolling by invitation, Jun1‐Mar18 2020   |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Dead group (no intervention) The individual which is defined as patient with all‐cause death                                                                                                                                                                                                                                                                                                              |                                            | Secondary (75 days): clinical characteristics, clinical course, cardiovascular comorbidity, Analysis of causes of death                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Treatment with mesenchymal stem cells for severe corona virus disease 2019(COVID‐19)                                                                                                                  | Biological: MSCs, biological: saline containing 1%, human serum albumin (solution of MSC                                                              | China/COVID‐19                                                   | 60, all, 18--70                                                  | Treatment                            | Experimental: mesenchymal stem cells (MSCs), conventional treatment plus MSCs participants will receive conventional treatment plus 3 times of MSCs ((4.0\*10E7 cells per time) intravenously at Day 0, Day 3, Day 6)                                                                                                                                                                                     | I, II                                      | Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | NCT04288102/Recruiting, May5‐Dec31 2020--2021          |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Placebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6)                                                                                                                                            |                                            | Secondary: proportion of patients in each classification of clinical critical treatment index (baseline, Days 7, 14, 28), all cause mortality on Day 28, invasive mechanical ventilation rate (Day 28), duration of oxygen therapy (Day 28), duration of hospitalization (Day 28), incidence of nosocomial infection (Day 28), CD4+ T cell count by flow cytometry in two groups (baseline, Day, 3, 6, 10, 14, 21, 28)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| The clinical study of carrimycin on treatment patients with COVID‐19                                                                                                                                  | Drug: carrimycin, drug: lopinavir/ritonavir tablets or arbidol or chloroquine phosphate, Drug: basic treatment                                        | --                                                               | 520, all, 18--75                                                 | Treatment                            | Experimental: carrimycin basic treatment + carrimycin                                                                                                                                                                                                                                                                                                                                                     | IV                                         | Primary (30 days): fever to normal time (day), pulmonary inflammation resolution time (HRCT) (day), negative conversion (%) of 2019‐nCOVRNA in gargle (throat swabs) at the end of treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | NCT04286503/Not yet recruiting, Feb23‐Feb28 2020--2021 |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Active comparator: lopinavir/ritonavir or arbidol or chloroquine phosphate any of basic treatment + lopinavir/ritonavir tablets or arbidol or chloroquine phosphate                                                                                                                                                                                                                                       |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Efficacy and safety of corticosteroids in COVID‐19                                                                                                                                                    | Drug: methylprednisolone                                                                                                                              | China/COVID‐19                                                   | 400, all, 18 years and older                                     | Treatment                            | Experimental; Pred group: methylprednisolone 1 mg/kg/day ivgtt for 7 days                                                                                                                                                                                                                                                                                                                                 | Not applicable                             | Primary (14 days): the incidence of treatment failure in 14 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | NCT04273321/Recruiting, Feb14‐May30 2020               |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | No intervention: con group                                                                                                                                                                                                                                                                                                                                                                                |                                            | Secondary: clinical cure incidence (14 days), the duration of virus change to negative (14 days), mortality at Day 30, ICU admission rate in 30 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19                                                                                                             | Drug: sarilumab, drug: placebo                                                                                                                        | United States/COVID‐19                                           | 400, all, 18 years and older                                     | Treatment                            | Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names: Kevzara®, REGN88, SAR153191                                                                                                                                                                                                                                                                                    | II, III                                    | Primary: time to resolution of fever for at least 48 hr without antipyretics for 48 hr (Up to Day 29), percentage of patients reporting each severity rating on a 6‐point ordinal scale (Day 15)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | NCT04315298/Recruiting, Mar16‐Mar16 2020--2021         |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Experimental: sarilumab low dose: single intravenous (IV) dose of sarilumab Other Names: Kevzara®, REGN88, SAR153191                                                                                                                                                                                                                                                                                      |                                            | Secondary (up to Day 29): time to improvement in oxygenation for at least 48 hr, mean change in the 6‐point ordinal scale, clinical status using the 6‐point ordinal scale, time to improvement in one category from admission using the 6‐point ordinal scale, time to resolution of fever for at least 48 hr without antipyretics by clinical severity, time to resolution of fever for at least 48 hr without antipyretics by baseline IL‐6 levels, time to improvement in oxygenation for at least 48 hr by clinical severity, time to improvement in oxygenation for at least 48 hr by baseline IL‐6 levels, time to resolution of fever and improvement in oxygenation for at least 48 hr, time to change in National Early Warning Score 2 (NEWS2) scoring system, time to score of \<2 maintained for 24 hr in NEWS2 scoring system, mean change in NEWS2 scoring system, number of days with fever, number of patients alive off oxygen, number of days of resting respiratory rate \>24 breaths/min, number of days with hypoxemia, number of days of supplemental oxygen use, time to saturation ≥94% on room air, number of ventilator free days in the first 28 days, number of patients requiring initiation of mechanical ventilation, number of patients requiring noninvasive ventilation, number of patients requiring the use of high flow nasal cannula, number of patients admitted into an intensive care unit, number of days of hospitalization among survivors, number of deaths due to any cause (up to Day 60), incidence of serious adverse events (Up to Day 60), incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection, Incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia, Incidence of hypersensitivity reactions, incidence of infusion reactions, incidence of gastrointestinal perforation, white blood cell count, hemoglobin levels, platelet count, creatinine levels, total bilirubin level, alanine aminotransferase level, aspartate aminotransferase level |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Placebo comparator: single intravenous (IV) dose of placebo to match sarilumab administration                                                                                                                                                                                                                                                                                                             |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Washed microbiota transplantation for patients with 2019‐nCoV infection                                                                                                                               | Other: washed microbiota transplantation, other: placebo                                                                                              | China/COVID‐19 complicated with refractory intestinal infections | 0, all, 14--70 complicated with refractory intestinal infections | Treatment                            | Experimental: observational group 5 u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy                                                                                                                                                                                                                                           | Not applicable                             | Primary (2 weeks): number of participants with improvement from severe type to common type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | NCT04251767/Withdrawn, Feb5‐Apr30 2020                 |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Placebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy                                                                                                                                                                                      |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Safety and immunity of Covid‐19 aAPC vaccine                                                                                                                                                          | Biological: pathogen‐specific aAPC                                                                                                                    | China/Covid‐19 infection                                         | 100, all, 6 months to 80 years                                   | Treat and Prevent Covid‐19 Infection | Experimental: the subjects will receive three injections of 5×10\^6 each Covid‐19/aAPC vaccine via subcutaneous injections                                                                                                                                                                                                                                                                                | I                                          | Primary (0--28 day): frequency of vaccine events, frequency of serious vaccine events, proportion of subjects with positive T cell response                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | NCT04299724/Recruiting, Feb15‐Dec31 2020--2024         |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | Secondary (0--28 day): mortality, duration of mechanical ventilation if applicable, proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), clinical improvement based on the 7‐point scale if applicable, lower Murray lung injury score if applicable (7 days after randomization)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Safety related factors of endotracheal intubation in patients with severe Covid‐19 pneumonia                                                                                                          | Severe covid‐19 pneumonia with ET                                                                                                                     | COVID‐19 endotracheal intubation                                 | 120, all, 18--90                                                 | Observational                        | Intervention details: other: severe covid‐19 pneumonia with ET, severe covid‐19 pneumonia undergoing endotracheal intubation                                                                                                                                                                                                                                                                              | --                                         | Primary:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | NCT04298814/Not yet recruiting, Mar7‐Jul30 2020        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | Success rate of intubation (the time span between 1 hr before intubation and 24 hr after intubation), infection rate of anesthesiologist (the time span between 1 hr before intubation and 14 days after intubation)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | Secondary:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | Extubation time (the time span between 1 hr before intubation and 30 days after intubation)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Immunity and safety of Covid‐19 synthetic minigene vaccine                                                                                                                                            | Biological: injection and infusion of LV‐SMENP‐DC vaccine and antigen‐specific CTLs                                                                   | China/COVID‐19                                                   | 100, all, 6 months to 80 years                                   | Treatment                            | Experimental: pathogen‐specific DC and CTLs patients will receive approximately 5 × 10^6^ LV‐DC vaccine and 1 × 10^8^ CTLs via subcutaneous injections and iv infusions, respectively                                                                                                                                                                                                                     | I                                          | Primary:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | NCT04276896/Recruiting, Mar24‐Dec31 2020--2024         |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           | II                                         | Clinical improvement based on the 7‐point scale (28 days after randomization), lower Murray lung injury score (7 days after randomization)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | Secondary (0--28 day): 28‐day mortality, duration of mechanical ventilation, duration of hospitalization, proportion of patients with negative RT‐PCR results (7 and 14 days after randomization), proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), frequency of vaccine/CTL events, frequency of serious vaccine/CTL events                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Phase I clinical trial in healthy adult                                                                                                                                                               | Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector)                                                                          | --                                                               | 108, all, 18--60                                                 | Prevention                           | Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18--60 years old                                                                                                                                                                                                                                                                                                           | I                                          | Primary (0--7 days postvaccination): safety indexes of adverse reactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | NCT04313127/Not yet recruiting, Mar1Dec20 2020--2022   |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Experimental: middle‐dose group                                                                                                                                                                                                                                                                                                                                                                           |                                            | Secondary (Day 14, 28, Month 3, 6 postvaccination):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Subjects received one dose of 1E11 vp Ad5‐nCoV at 18--60 years old                                                                                                                                                                                                                                                                                                                                        |                                            | Safety indexes of adverse events (0--28 days postvaccination), safety indexes of SAE (0--28 days, within 6 mouths postvaccination), safety indexes of lab measures (pre‐vaccination, Day 7 postvaccination), immunogencity indexes of GMT(ELISA) (Day 14, 28, Month 3, 6 postvaccination), immunogencity indexes of GMT (pseudoviral neutralization test method), immunogencity indexes of seropositivity rates, immunogencity indexes of seropositivity rates (pseudoviral neutralization test method, immunogencity indexes of GMI (ELISA), immunogencity indexes of GMI (pseudoviral neutralization test method), immunogencity indexes of GMC (Ad5 vector), immunogencity indexes of GMI (Ad5 vector), immunogencity indexes of cellular immune                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Experimental: high‐dose group                                                                                                                                                                                                                                                                                                                                                                             |                                            | Other (day、14,28, Month3,6 postvaccination):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Subjects received one dose of 1.5E11vp Ad5‐nCoV at 18--60 years old                                                                                                                                                                                                                                                                                                                                       |                                            | Consistency analysis(ELISA and pseudoviral neutralization test method), Dose‐response relationship (Humoral immunity), Persistence analysis of anti‐S protein antibodies, Time‐dose‐response relationship (Humoral immunity), Dose‐response relationship (cellular immunity), Persistence analysis of cellular immuse, Time‐dose‐response relationship (cellular immunity)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Development and verification of a new coronavirus multiplex nucleic acid detection system                                                                                                             | Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform                                                                       | China/COVID‐19                                                   | 100, all, 16 years to 100 years                                  | Diagnostic                           | Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform                                                                                                                                                                                                                                                                                                                           | --                                         | Primary:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | NCT04311398/Not yet recruiting, Mar14‐Dec1, 2020       |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | We use the new QIAstat‐Dx fully automatic multiple PCR detection platform to test the enrolled patients                                                                                                                                                                                                                                                                                                   |                                            | Sensitivity, spectivity turnaround time of the New QIAstat‐Dx fully automatic multiple PCR detection platform (3 months)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Hydroxychloroquine treatment for severe COVID‐19 pulmonary infection (HYDRA Trial)                                                                                                                    | Drug: hydroxychloroquine, drug: placebo oral tablet                                                                                                   | COVID‐19 severe acute respiratory syndrome                       | 500, all, 18--0                                                  | Treatment                            | Active comparator: treatment                                                                                                                                                                                                                                                                                                                                                                              | III                                        | Primary (up to120 days):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | NCT04315896/Not yet recruiting, Mar23‐Mar22 2020--2012 |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Hydroxychloroquine tablet 200 mg every 12 hr for 10 days                                                                                                                                                                                                                                                                                                                                                  |                                            | All‐cause hospital mortality                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Placebo comparator: placebo                                                                                                                                                                                                                                                                                                                                                                               |                                            | Secondary (up to120 days):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | identical placebo, one tablet every 12 hr for 10 days                                                                                                                                                                                                                                                                                                                                                     |                                            | Length of hospital stay, Need of mechanical ventilation, ventilator free days, Grade 3--4 adverse reaction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Tocilizumab in COVID‐19 pneumonia (TOCIVID‐19)                                                                                                                                                        | Drug: tocilizumab Injection                                                                                                                           | Italy/COVID‐19 pneumonia                                         | 330, child, adult, older adult, child, adult, older adult        | Treatment                            | Experimental: Tocilizumab Injection                                                                                                                                                                                                                                                                                                                                                                       | II                                         | Primary (up to 1 month):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | NCT04317092/Recruiting, Mar19‐Dec19 2020--2022         |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Tocilizumab 8 mg/kg (up to a maximum of 800 mg per dose), with an interval of 12 hr                                                                                                                                                                                                                                                                                                                       |                                            | One‐month mortality rate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | Secondary (up to 1 month):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | interleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient\'s discharge, Remission of respiratory symptoms                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Mesenchymal stem cell NestCell® to treat patients with severe COVID‐19 pneumonia                                                                                                                      | Biological: NestCell®                                                                                                                                 | COVID‐19 pneumonia                                               | 6, all, 18 years and older                                       | Treatment                            | Experimental: NestCell®:                                                                                                                                                                                                                                                                                                                                                                                  | I                                          | Primary (28 days):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | NCT04315987/Not yet recruiting, Apr‐Jun 2020           |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | All patients will receive conventional treatment plus 3 times of 1 × 106 cells/kg body weight intravenously on Day1, Day3, and Day7                                                                                                                                                                                                                                                                       |                                            | Disappear time of ground‐glass shadow in the lungs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | Secondary:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | Rate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| CD24Fc as a non‐antiviral immunomodulator in COVID‐19 treatment                                                                                                                                       | Drug: CD24Fc, drug: placebo                                                                                                                           | United States/severe coronavirus disease (COVID‐19)              | 230, all, 18 years and older                                     | Treatment                            | Experimental: CD24Fc treatment                                                                                                                                                                                                                                                                                                                                                                            | III                                        | Primary (14 days):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | NCT04317040/Not yet recruiting,May‐May 2020--2022      |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Single dose at Day 1, CD24Fc, 480 mg, diluted to 100 ml with normal saline, IV infusion in 60 min                                                                                                                                                                                                                                                                                                         |                                            | Improvement of COVID‐19 disease status secondary (14 days):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Placebo comparator: placebo                                                                                                                                                                                                                                                                                                                                                                               |                                            | Conversion rate of clinical status at Day 8 (7 days), conversion rate of clinical status at Day 15, hospital discharge time, all cause of death, duration of mechanical ventilation, duration of pressors, duration of ECMO, duration of oxygen therapy, length of hospital stay, absolute lymphocyte count                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Single dose at Day 1, normal saline solution 100 ml, IV infusion in 60 min                                                                                                                                                                                                                                                                                                                                |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Acute kidney injury in patients hospitalized with COVID‐19                                                                                                                                            | --                                                                                                                                                    | China/COVID‐19 acute kidney injury‐kidney function               | 287, all, 18 years and older                                     | Observational                        | Acute kidney injury:                                                                                                                                                                                                                                                                                                                                                                                      | --                                         | Primary (up to 60 days):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | NCT04316299/Completed, Feb 26‐Mar8 2020                |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | COVID‐19 patients with acute kidney injury                                                                                                                                                                                                                                                                                                                                                                | Rate of death, the length of hospital stay | Rate of acute kidney injury                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | nonacute kidney injury:                                                                                                                                                                                                                                                                                                                                                                                   |                                            | Secondary (up to 60 days):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | COVID‐19 patients without acute kidney injury                                                                                                                                                                                                                                                                                                                                                             |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Phase I clinical trial in healthy adult                                                                                                                                                               | Logical: recombinant novel coronavirus vaccine (adenovirus type 5 vector)                                                                             | COVID‐19                                                         | 108, all, 18--60                                                 | Treatment                            | (Adenovirus Type 5 Vector)                                                                                                                                                                                                                                                                                                                                                                                | I                                          | Primary (0--7 days postvaccination):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | NCT04313127/Not yet recruiting, Mar19‐Dec20 2020--2021 |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Experimental: low‐dose group                                                                                                                                                                                                                                                                                                                                                                              |                                            | Safety indexes of adverse reactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Subjects received one dose of 5E10 vp Ad5‐nCoV at 18--60 years old                                                                                                                                                                                                                                                                                                                                        |                                            | Secondary (0--28 days postvaccination, within 6 mouths postvaccination):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Experimental: middle‐dose group                                                                                                                                                                                                                                                                                                                                                                           |                                            | Safety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Subjects received one dose of 1E11 vp Ad5‐nCoV at 18--60 years old                                                                                                                                                                                                                                                                                                                                        |                                            | Other (Day 14,28, Month 6 postvaccination):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Experimental: high‐dose group subjects received one dose of 1.5E11vp Ad5‐nCoV at 18--60 years old                                                                                                                                                                                                                                                                                                         |                                            | Consistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Favipiravir combined with tocilizumab in the treatment of corona virus disease 2019                                                                                                                   | Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab                                                                     | China, COVID‐19                                                  | 150, all, 18--65                                                 | Treatment                            | Experimental: favipiravir combined with tocilizumab group                                                                                                                                                                                                                                                                                                                                                 | Not applicable                             | Primary (3 months):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | NCT04310228/Recruiting, Mar8‐May 2020                  |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Favipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.                                                                                                                                                                                                  |                                            | Clinical cure rate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Tocilizumab: the first dose is 4--8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg               |                                            | Secondary (14 days after taking medicine):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Active comparator: favipiravir group                                                                                                                                                                                                                                                                                                                                                                      |                                            | Viral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days                                                                                                                                                                                                                |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Active comparator: tocilizumab group                                                                                                                                                                                                                                                                                                                                                                      |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | The first dose is 4--8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg                            |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Novel coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells                                                                                                              | Biological: dental pulp mesenchymal stem cells                                                                                                        | ‐COVID‐19                                                        | 24, all, 18--75                                                  | Treatment                            | Experimental: pulp mesenchymal stem cells 1. 3, 7 days to increase the injection of mesenchymal stem cells                                                                                                                                                                                                                                                                                                | Early Phase I                              | Primary (14 days):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | NCT04302519/Not yet Recruiting, Mar5‐Jul30 2020--2021  |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | Disppear time of ground‐glass shadow in the lungs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | Secondary:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | Absorption of lung shadow absorption by CT Scan‐Chest (7, 14, 28, and 360 days), Changes of blood oxygen (3, 7, and 14 days)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Multicenter clinical study on the efficacy and safety of Xiyanping injection in the treatment of new coronavirus infection pneumonia (general and severe)                                             | Drug: lopinavir/ritonavir tablets combined with Xiyanping injection drug: lopinavir/ritonavir treatment                                               | COVID‐19                                                         | 80, all, 18--100                                                 | Treatment                            | Experimental: experimental group of ordinary COVID‐19:                                                                                                                                                                                                                                                                                                                                                    | Not applicable                             | Primary:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | NCT04295551/Not yet Recruiting, Mar14‐Apr14 2020--2021 |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Xiyanping injection, 10--20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7--14 days,                                                                                                                                                                                                                        |                                            | Clinical recovery time (up to Day 28)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Active comparator: control group of ordinary COVID‐19:                                                                                                                                                                                                                                                                                                                                                    |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Lopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization                                                                                                                                                                                                                                                                                                        |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Experimental: experimental group of severe COVID‐19:                                                                                                                                                                                                                                                                                                                                                      |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Xiyanping injection, 10--20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7--14 days                                                                                                                                                                                                                         |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Prognostic factors of patients with COVID‐19                                                                                                                                                          | --                                                                                                                                                    | China/SARS‐CoV‐2 outcome, fatal                                  | 201, all, 18 years and older                                     | Prognostic                           | SARS‐CoV‐2Outcome, fatal                                                                                                                                                                                                                                                                                                                                                                                  | --                                         | Primary (30 days):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | NCT04292964/Completed Mar1‐Mar13 2020                  |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | all‐cause mortality                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | Secondary (15 days):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | all‐cause mortality,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | Severe state                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Chloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting                                                                                                                    | Drug: chloroquine, drug: placebo                                                                                                                      | COVID19 coronavirus acute respiratory illnesses                  | 10,000, all, 16 years and older                                  | Prevention                           | Experimental: chloroquine:                                                                                                                                                                                                                                                                                                                                                                                | Not applicable                             | Primary (approximately 100 days):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | NCT04303507/Not yet recruiting, May‐May 2020--2022     |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | a loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months                                                                                                                                                                                                                                                                                   |                                            | Number of symptomatic COVID‐19 infections                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Placebo comparator: placebo                                                                                                                                                                                                                                                                                                                                                                               |                                            | Secondary (approximately 100 days):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | Symptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | Other (approximately 100 days):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | Drug exposure‐protection relationship                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Yinhu Qingwen decoction for the treatment of mild/common CoVID‐19                                                                                                                                     | Drug: YinHu QingWen decoction, drug: YinHu QingWen decoction(low dose), other: Chinese medicine treatment, other: standard western medicine treatment | China/CoVID‐19 Chinese medicine                                  | 300, all, 18 years and older                                     | Treatment                            | Experimental: Yin Hu Qing Wen decoction group                                                                                                                                                                                                                                                                                                                                                             | II                                         | Primary (up to 28 days):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | NCT04278963/Active, Not Recruiting, Feb27‐Jan 2020     |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Based on the standard western medicine treatment, the patients will be given Yinhu Qingwen decoction (granula) for 10 days.                                                                                                                                                                                                                                                                               | III                                        | Mean clinical recovery time                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Drug: YinHu QingWen decoction YinHu QingWen decoction (granula) consits of 11 Chinese herbal medicine as honeysuckle, *Polygonum cuspidatum*, Schizonepeta, Longspur epimedium, and so forth. The decoction granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days                             |                                            | Secondary (up to 28 days):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Other: standard western medicine treatment treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China                                                                                                                                                                                                                |                                            | Time to CoVID‐19 RT‐PCR negative in upper respiratory tract specimen, change (reduction) in CoVID‐19 viral load in upper respiratory tract specimen as assessed by area under viral load curve, time to defervescence (in those with fever at enrollment), time to cough reported as mild or absent (in those with cough at enrollment rated severe or moderate), time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Placebo comparator: Yinhu Qingwen decoction low‐dose group                                                                                                                                                                                                                                                                                                                                                |                                            | Frequency of requirement for supplemental oxygen or noninvasive ventilation, frequency of respiratory progression, severe case incidence, proportion of rehospitalization or admission to ICU, all‐cause mortality, frequency of serious adverse events                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Based on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen decoction (granula) for 10 days                                                                                                                                                                                                                                                                    |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Drug: YinHu QingWen decoction (low dose) this intervention is given as 10% dose of YinHu QingWen decoction (granula). The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days                                                                                                               |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Other: standard western medicine treatment standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China                                                                                                                                                                                      |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Active comparator: integrated Chinese and western medicine group                                                                                                                                                                                                                                                                                                                                          |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Based on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into three times (once with 200 ml). The Chinese medicine decoction will be given 200 ml per time, three times a day for 10 days                  |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Other: Chinese medicine treatment                                                                                                                                                                                                                                                                                                                                                                         |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days                                                                                                                                                                                                                                                                 |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Other: standard western medicine treatment                                                                                                                                                                                                                                                                                                                                                                |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China                                                                                                                                                                                                                                 |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Prognositc factors in COVID‐19 patients complicated with hypertension                                                                                                                                 | --                                                                                                                                                    | China, COVID‐19                                                  | 0, all, 18--100                                                  | Prognostic                           | ACEI treatment                                                                                                                                                                                                                                                                                                                                                                                            | --                                         | Primary (up to 28 days):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | NCT04272710/Withdrawn, Jan25‐Apr30 2020                |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | hypertension patients with ACEI treatment when suffered with novel coronavirus infection in China                                                                                                                                                                                                                                                                                                         |                                            | Occupancy rate in the intensive care unit, mechanical ventilation, death                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Control                                                                                                                                                                                                                                                                                                                                                                                                   |                                            | Secondary (up to 28 days):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | hypertension patients without ACEI treatment when suffered with novel coronavirus infection in China                                                                                                                                                                                                                                                                                                      |                                            | All cause mortality, time from onset of symptoms to main outcome and its components, time to clinical recovery                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Evaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID‐19) | Drug: bromhexine hydrochloride tablets, drug: arbidol hydrochloride granules, drug: recombinant human interferon α2b spray, drug: favipiravir tablets | China, novel coronavirus pneumonia 2019‐nCoV                     | 60, all, 18--80                                                  | Treatment                            | Experimental: group A treatment group:                                                                                                                                                                                                                                                                                                                                                                    | Not applicable                             | Primary (within 14 days from the start of medication):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | NCT04273763/Enrolling by invitation, Feb16‐Apr30 2020  |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Bromhexine hydrochloride tablets, arbidol hydrochloride granules:                                                                                                                                                                                                                                                                                                                                         |                                            | Time to clinical recovery after treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. Arbidol hydrochloride granules is recommended but not enforced to use                                                                                                                                                                                                        |                                            | Secondary (within 14 days from the start of medication):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Recombinant human interferon α2b spray:                                                                                                                                                                                                                                                                                                                                                                   |                                            | Rate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days))                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection                                                                                                                                                                                                                                                                               |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Favipiravir tablets                                                                                                                                                                                                                                                                                                                                                                                       |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Active comparator; group B control group:                                                                                                                                                                                                                                                                                                                                                                 |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Drug: arbidol hydrochloride granules                                                                                                                                                                                                                                                                                                                                                                      |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use                                                                                                                                                                                                        |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Drug: recombinant human interferon α2b spray                                                                                                                                                                                                                                                                                                                                                              |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection                                                                                                                                                                                                                                                                               |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Various combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial                                                             | Drug: oral                                                                                                                                            | Thailand, coronavirus infections COVID19                         | 80, all, 16--100                                                 | Treatment                            | Experimental: oseltamivir plus chloroquin in mild COVID19                                                                                                                                                                                                                                                                                                                                                 | III                                        | Primary (Up to 24 weeks):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | NCT04303299/Not yet recruiting, Mar15‐Nov30 2020       |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Oseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19                                                                                                                                                                                                                                                                                                                               |                                            | SARS‐CoV‐2 eradication time                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Experimental: lopinavir and ritonavir plus favipiravir                                                                                                                                                                                                                                                                                                                                                    |                                            | Secondary (up to 24 weeks):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Lopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19                                                                                                                                                                                                                          |                                            | Number of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Experimental: lopinavir and ritonavir plus oseltamivir in mild COVID19                                                                                                                                                                                                                                                                                                                                    |                                            | Other (up to 24 weeks):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4--6 mg/kg In mild COVID19                                                                                                                                                                                                                                                                                                                  |                                            | Number of patient with acute respiratory distress syndrome recovery                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Experimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19                                                                                                                                                                                                                                                                                                                              |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4--6 mg/kg in moderate to critically ill COVID19                                                                                                                                                                                                                                                                                            |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Experimental: favipiravir lopinavir/ritonavir for mod. To severe                                                                                                                                                                                                                                                                                                                                          |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19                                                                                                                                                                                                  |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Experimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe                                                                                                                                                                                                                                                                                                                                      |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Combination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4--6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19                                                                                                                                                                                                                                |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Experimental: darunavir/ritonavir favipiravir chloroquine mod‐severe                                                                                                                                                                                                                                                                                                                                      |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19                                                                                                                                                     |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | No intervention: conventional qurantine                                                                                                                                                                                                                                                                                                                                                                   |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Patient who unwilling to treatment and willing to quarantine in mild COVID19                                                                                                                                                                                                                                                                                                                              |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Yinhu Qingwen Granula for the treatment of severe CoVID‐19                                                                                                                                            | Drug: Yinhu Qingwen granula, drug: Yin Hu Qing Wen granula (low does), other: standard medical treatment                                              | China, COVID‐19 severe pneumonia Chinese medicine                | 116, all, 18 years and older                                     | Treatment                            | Experimental:                                                                                                                                                                                                                                                                                                                                                                                             | II                                         | Primary (Day 10):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | NCT04310865/Not yet recruiting, Mar20‐Jun30 2020--2021 |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Yinhu Qingwen granula group:                                                                                                                                                                                                                                                                                                                                                                              |                                            | changes in the ratio of PaO2 to FiO2 from baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Drug: Yinhu Qingwen Granula                                                                                                                                                                                                                                                                                                                                                                               |                                            | Secondary (up to 30 days):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Yinhu Qingwen granula is a kind of herbal granula made from "Yinhu Qingwen Decoction," which consits of 11 Chinese herbal medicine as honeysuckle, *Polygonum cuspidatum*, schizonepeta, *Longspur epimedium*, etc. The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days.                |                                            | PaO2, blood oxygen saturation (SpO2), clinical status rating on the 7‐point ordinal scale, time to clinical improvement, duration (hours) of noninvasive mechanical ventilation or high‐flow nasal catheter oxygen inhalation use, duration (hours) of invasive mechanical ventilation use, duration (hours) of extracorporeal membrane oxygenation (ECMO) use, duration (days) of oxygen use, The proportion of the patients reporting 2019‐nCoV RT‐PCR negativity at Day 10 after treatment, the counts/percentage of lymphocyte, time to hospital discharge with clinical recovery from the randomization, the incidence of critical status conversion in 30 days, all‐cause mortality within 30 days, frequency of severe adverse drug events                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.                                                                                                                                                                                              |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Placebo comparator: Yinhu Qingwen granula low‐dose group:                                                                                                                                                                                                                                                                                                                                                 |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Drug: Yin Hu Qing Wen granula (low does). This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).                                                                                                                                                                                              |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.                                                                                                                                                                                              |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Clinical characteristics and long‐term prognosis of 2019‐nCoV infection in children                                                                                                                   | --                                                                                                                                                    | China, 2019‐nCoV                                                 | 500, all, up to 18 years                                         | Prognosis                            | 2019‐nCoV infection group                                                                                                                                                                                                                                                                                                                                                                                 | --                                         | Primary (6 months):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | NCT04270383/Not yet recruiting, Feb15‐Dec30 2020       |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Children hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019‐nCoV infection group                                                                                                                                                                                                                                                     |                                            | The cure rate of 2019‐nCoV, the improvement rate of 2019‐nCoV, the incidence of long‐term adverse outcomes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Control group Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019‐nCoV infection group are classified as the control group                                                                                                                                                                                                     |                                            | Secondary (2 weeks):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | Duration of fever, duration of respiratory symptoms, duration of hospitalization, number of participant(s) need intensive care, number of participant(s) with acute respiratory distress syndrome, number of participant(s) with extra‐pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al., number of participant(s) who died during the trial (10 months)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| The effect of T89 on improving oxygen saturation and clinical symptoms in patients with COVID‐19                                                                                                      | Drug: T89                                                                                                                                             | Coronavirus disease 2019 novel coronavirus pneumonia             | 120, all, 18--85                                                 | Treatment                            | Experimental: The T89 treatment group Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID (every morning and evening), for 10 days (depending on clinical need and practicability, the use can be extended for up to 14 days) | Not applicable                             | Primary (Day −1 to 10): the time to oxygen saturation recovery to normal level (≥97%), the proportion of patients with normal level of oxygen saturation(≥97%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | NCT04285190/Not yet recruiting, Feb26‐Sep15 2020       |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | No intervention: the blank control group                                                                                                                                                                                                                                                                                                                                                                  |                                            | Secondary (Day −1 to 10):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | All subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days.                                                                                                                                                                                                        |                                            | The degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, and so forth, the time to the myocardial enzyme spectrum recovery to normal after treatment, the proportion of the patients with normal myocardial enzyme spectrum after treatment, the time to the electrocardiogram recovery to normal level after treatment, the proportion of the patients with normal electrocardiogram after treatment, the time to the hemodynamics recovery to normal after treatment, the proportion of the patients with normal hemodynamics after treatment, the time to exacerbation or remission of the disease after treatment, the proportion of the patients with exacerbation or remission of disease after treatment, the proportion of patients who need other treatment (e.g., heparin, anticoagulants) due to microcirculation disorders, the all‐cause mortality rate, the proportion of patients with acidosis, the total duration of the patients in‐hospital, the total duration of oxygen inhalation during treatment, the oxygen flow rate during treatment, the oxygen concentration during treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Immunoregulatory therapy for 2019‐nCoV                                                                                                                                                                | Drug: PD‐1 blocking antibody + standard treatment, drug: Thymosin + standard treatment, other: standard treatment                                     | ‐2019 nCoV, PD‐1                                                 | 120, all, 18 years and older                                     | Treatment                            | Experimental: PD‐1 group                                                                                                                                                                                                                                                                                                                                                                                  | II                                         | Primary (7 days):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | NCT04268537/Not yet recruiting, Feb10‐Oct31 2020       |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Anti‐PD‐1 antibody, 200 mg, IV, one time                                                                                                                                                                                                                                                                                                                                                                  |                                            | lung injury score                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Experimental: thymosin group                                                                                                                                                                                                                                                                                                                                                                              |                                            | Secondary:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Thymosin, 1.6 mg sc qd, last for 5 days                                                                                                                                                                                                                                                                                                                                                                   |                                            | Absolute lymphocyte counts (7, 14 and 28 days), serum level of CRP, PCT and IL‐6 (3, 7 and 14 days), SOFA score (7 days), all cause mortality rate (28 days), ventilation free days (28 days), ICU free days (up to 28 days)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Placebo comparator: control group stand treatment                                                                                                                                                                                                                                                                                                                                                         |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Tocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19                                                                                                                      | Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy                                                           | China, Covid‐19 SARS cytokine storm (and 2 more...)              | 120, all, 18--80                                                 | Observational                        | Tocilizumab                                                                                                                                                                                                                                                                                                                                                                                               | --                                         | Primary (up to 14 days):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | NCT04306705/Recruiting, Feb20‐Jun20 2020               |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Subjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no \<60 min. Tocilizumab was administered according---continuous renal replacement therapy                                                                                                                                                                                  |                                            | Proportion of participants with normalization of fever and oxygen saturation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Femoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label                                                                                                                                                                                                                                                       |                                            | Secondary:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Standard care                                                                                                                                                                                                                                                                                                                                                                                             |                                            | Duration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Standard of care therapy per local written policies or guidelines                                                                                                                                                                                                                                                                                                                                         |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
| Sars‐CoV2 seroconversion among front line medical and paramedical staff in emergency, intensive care units and infectious disease departments during the 2020 Epidemic                                | Other: blood sample                                                                                                                                   | France, Sars‐CoV2                                                | 1,000, all, child, adult, older adult                            | Other                                | Caregiver                                                                                                                                                                                                                                                                                                                                                                                                 | Not applicable                             | Primary (3 months):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | NCT04304690/Recruiting, Mar16‐Oct16 2020               |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | caregivers from emergency, ICU, virology and infectious disease services:                                                                                                                                                                                                                                                                                                                                 |                                            | Quantify the proportion of patients with documented Sars‐CoV2 infection among medical and paramedical staff                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      | Two blood samples at T0 and 3 months                                                                                                                                                                                                                                                                                                                                                                      |                                            | Secondary (3 months):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                        |
|                                                                                                                                                                                                       |                                                                                                                                                       |                                                                  |                                                                  |                                      |                                                                                                                                                                                                                                                                                                                                                                                                           |                                            | Identification of risk factors for seroconversion, quantify the proportion of asymptomatic infections among staff who have seroconverted, describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                        |
+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------+
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### 5.3.1. Reverse transcriptase polymerase chain reaction {#jcp29735-sec-0170}

Despite being the diagnostic gold standard, pathogenic lab testing is a rather time‐consuming procedure, with unavoidable false‐positive results (Wang, Kang, et al., [2020](#jcp29735-bib-0074){ref-type="ref"}). It is recommended that lab testing should be performed, as soon as the patient is identified as a "person under investigation" (PUI). Viral nucleic acid required for an RT‐PCR test is usually extracted from secretions of the lower respiratory tract, for example, bronchoalveolar lavage; however, tracheal aspirate or sputum can also be used (Chu et al., [2020](#jcp29735-bib-0023){ref-type="ref"}; Corman et al., [2020](#jcp29735-bib-0028){ref-type="ref"}). Since the onset of the epidemic, several factors have been found to affect the final efficiency of nucleic acid testing, that is, availability, quality, stability, and reproducibility of detection kits. In most of the cases, the tests need to be repeated for several times (Wang, Kang, et al., [2020](#jcp29735-bib-0074){ref-type="ref"}), as the estimated detection rate of the test falls in an underwhelming range of 30--50% (Chu et al., [2020](#jcp29735-bib-0023){ref-type="ref"}; Corman et al., [2020](#jcp29735-bib-0028){ref-type="ref"}; Zhang et al., [2020](#jcp29735-bib-0094){ref-type="ref"}). In spite of being a valuable asset, the undesirable false‐negative results of RT‐PCR have prompted careful clinical and etiological evaluation of COVID‐19 in suspected cases as the first‐line diagnostic method (Zu et al., [2020](#jcp29735-bib-0098){ref-type="ref"}).

### 5.3.2. Computed tomography (CT) {#jcp29735-sec-0180}

CT has proved to be of great value in diagnosis of the COVID‐19‐associated pneumonia, as it provides major evidence, that cannot readily be obtained with alternative methods. It is true that CT is a reliable imaging modality in subtle detection of viral pneumonia and screening of suspected cases; however, it should be noted that many pulmonary diseases of inflammatory nature share similar radiographic findings (Wang, Kang, et al., [2020](#jcp29735-bib-0074){ref-type="ref"}). The majority of patients with COVID‐19 present with GGO in their chest CT, which later progress into multilobar consolidations. There have been several reports of rounded opacities, which are sometimes peripherally distributed in the lung (Chung et al., [2020](#jcp29735-bib-0025){ref-type="ref"}; Huang et al., [2020](#jcp29735-bib-0040){ref-type="ref"}). In contrast to CT, plain chest radiography (CXR) has not been recommended as a first‐line imaging method, because this modality does not provide the clarity viewed on CT scans, especially in the early stages of pulmonary infection (Ng et al., [2020](#jcp29735-bib-0059){ref-type="ref"}). Nevertheless, CXR is capable of recording pathologic changes in patients with severely progressed COVID‐19, as the bilateral multifocal consolidations present in these patients are too dense to be missed. The notorious "white lung" appearance can be optimally viewed on CXRs of critically ill patients (Zu et al., [2020](#jcp29735-bib-0098){ref-type="ref"}). CT resulted in diagnosis of 14,840 new cases as of February 13, 2020 (Zu et al., [2020](#jcp29735-bib-0098){ref-type="ref"}). Therefore, slice chest CT is an adequately sensitive and reliable method in early detection of pneumonia in patients with COVID‐19 (Chan et al., [2020](#jcp29735-bib-0010){ref-type="ref"}; Ng et al., [2020](#jcp29735-bib-0059){ref-type="ref"}).

### 5.3.3. Novel approaches: Artificial intelligence‐based technologies {#jcp29735-sec-0190}

Depp learning, as a novel AI‐based modality might be able to analyze radiographic features of COVID‐19, and help clinicians provide an accurate clinical diagnosis based on a precedented pattern (Wang, Kang, et al., [2020](#jcp29735-bib-0074){ref-type="ref"}). As part of recent advancements, Convolutional Neural Network (CNN), a class of deep neural networks, has been shown to be capable of medical image analysis. To this date, CNN has been successfully employed in investigations on the nature of pulmonary nodules reported in CT images, diagnosis of pneumonia in children based on CXR, and image recognition in cystoscopy videos (Choe et al., [2019](#jcp29735-bib-0021){ref-type="ref"}; Kermany et al., [2018](#jcp29735-bib-0042){ref-type="ref"}; Negassi, Suarez‐Ibarrola, Hein, Miernik, & Reiterer, [2020](#jcp29735-bib-0058){ref-type="ref"}; Wang et al., [2018](#jcp29735-bib-0073){ref-type="ref"}).

The 21st century has seen many AI‐based models to be incorporated in several scientific fields, particularly imaging studies. Diagnostic AI‐based models might actually be a forward leap in tasks that simply cannot be handled by manpower, especially risk prioritization, that can greatly help improve patient turnaround time. Given the shortage of human resources and inadequate number of hospital beds in a country like China, AI‐based models for analysis of CXR and CT scans can be useful in ruling out irrelevant cases, and resource‐wise admission of patients to the hospitals (Kim, [2020](#jcp29735-bib-0043){ref-type="ref"}).

6. PREDICTION {#jcp29735-sec-0200}
=============

Recent studies focused on prognosis of COVID‐19 concluded that the load of SARS‐CoV‐2 RNA in blood (RNAemia) is correlated with Cytokine Release Storm (CRS) and poor prognosis of the disease. In one particular study, scientists used Generalized Linear Models to generate a prediction model for natural history of disease based on the *C* ~t~ value of real‐time RT‐PCR results. They reported that traceable amounts of SARS‐CoV‐2 RNA was detected in blood plasma of 15% of COVID‐19 positive patients enrolled at the study. Their findings drew a direct link between serum markers and disease severity, as RNAemia and high levels of IL‐6 (nearly 10‐fold) were exclusively reported in critically ill patients. Interestingly, there was also an association between the extremely high levels of IL‐6 with the incidence of RNAemia (*R* = 0.902) in patients. Findings also suggested that vital signs of patients were also affected by high levels of both serum markers (*R* = 0.682). According to this study, IL‐6 might be of clinical value in identification and treatment of patients with an excessive inflammatory response (Chen, Zhao, et al., [2020](#jcp29735-bib-0015){ref-type="ref"}). Table [3](#jcp29735-tbl-0003){ref-type="table"} (Chen, Zhao, et al., [2020](#jcp29735-bib-0015){ref-type="ref"}; Yan et al., [2020](#jcp29735-bib-0088){ref-type="ref"}) and Table [4](#jcp29735-tbl-0004){ref-type="table"} represent 2020 studies on prognosis of COVID‐19 infected patients and related clinical trials, respectively.

7. THERAPY {#jcp29735-sec-0210}
==========

Scientists have made strenuous efforts to come up with an effective regimen for successful treatment of COVID‐19 (Gao, Tian, & Yang, [2020](#jcp29735-bib-0033){ref-type="ref"}). Table [3](#jcp29735-tbl-0003){ref-type="table"} (Chen, Guo, et al., [2020](#jcp29735-bib-0011){ref-type="ref"}; Fan et al., [2020](#jcp29735-bib-0032){ref-type="ref"}; Han et al., [2020](#jcp29735-bib-0037){ref-type="ref"}; Lan et al., [2020](#jcp29735-bib-0049){ref-type="ref"}; Li, Zhang, et al., [2020](#jcp29735-bib-0050){ref-type="ref"}; Li, Hu, et al., [2020](#jcp29735-bib-0052){ref-type="ref"}; Lim et al., [2020](#jcp29735-bib-0053){ref-type="ref"}; Liu et al., [2020](#jcp29735-bib-0054){ref-type="ref"}; Liu et al., [2020](#jcp29735-bib-0054){ref-type="ref"}; Wu et al., [2020](#jcp29735-bib-0083){ref-type="ref"}; Wu & McGoogan, [2020](#jcp29735-bib-0084){ref-type="ref"}), Tables [4](#jcp29735-tbl-0004){ref-type="table"} and [5](#jcp29735-tbl-0005){ref-type="table"} (Zhang & Liu, [2020](#jcp29735-bib-0093){ref-type="ref"}) represent 2020 studies on treatment of COVID‐19 infected patients, related clinical trials and available therapeutic options, respectively.

###### 

Therapeutic options that are available for the treatment of novel coronaviruses (cell line, animal, and human studies)

  ---------------------- ------------------------------------------------ ----------------------------- --------------------------------------------------------------- --------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  General treatment      Nutritional interventions, targets or function   Vit A                         Measles virus, measles‐related pneumonia, HIV, avian CoV, IBV                                                 Upregulating the elements of the innate immune, Making the cells refractory to infection
                                                                          B vit                         MERS‐CoV                                                                                                      Enhancing immune system, Inhibiting the of neutrophil infiltration into the lungs, Anti‐inflammatory effects during ventilator‐induced lung injury
                                                                          Vit C                         Avian CoV                                                                                                     Supporting immune functions, protecting against CoV infection, preventing of the lower respiratory tract infections
                                                                          Vit D                         Bovine CoV                                                                                                    Triggering the maturation of immune cells
                                                                          Vit E                         Coxsackievirus, bovine CoV                                                                                    Antioxidant function
                                                                          Omega‐3 PUFA                  Influenza virus, HIV                                                                                          Attenuating the replication of influenza virus
                                                                          Selenium                      Influenza virus, avian CoV                                                                                    Antioxidant function, inducing immune response
                                                                          Zinc                          Influenza virus, avian CoV, SARS‐CoV                                                                          Maintenance/development of innate and adaptive immune systems simultaneously
                                                                          Iron                          Viral mutations                                                                                               Enhancing the immune system
                         Immunoenhancers                                  IFNs                          SARS‐CoV, MERS‐CoV                                                                                            Acting as apart of the innate immune response, Inhibiting the replication of CoVs in animal and human
                                                                          IVIg                          SARS‐CoV                                                                                                      Increasing the viscosity in hypercoagulable states
                                                                          Ta1                           SARS‐CoV                                                                                                      Restoring the homeostasis of the immune system, Increasint the resistance glucocorticoid‐induced death of thymocyte
                                                                          TP5, munox                    Restore antibody production                                                                                   Restoring antibody production, Enhancing the antibody response, As adjuvant treatment
                                                                          Levamisole                    Immunostimulant/immunosuppressive agent                                                                       Increasing the functions of cellular immunity, Act as immunostimulant agent or immunosuppressive agent through dose‐ and time‐dependent manner, reversing the depressed helper/inducer lymphocytes
                                                                          Cyclosporine A                SARS‐CoV, avian infectious bronchitis virus                                                                   Both facilitating or inhibiting virus replication, blocking the all genera replication of CoV
                                                                          CTM                           Glycyrrhizin, Baicalin, Ginseng                                 SARS‐CoV, avian infectious bronchitis virus   Enhancing host immunity, Inhibiting the replication of SARS‐associated virus and SARS‐CoV, Enhancing the specific‐antibody responses
  Specific treatments    Protease inhibitors                              3C‐like inhibitors            Cinanserin,                                                     SARS‐CoV                                      Act as serotonin receptor antagonist, Inhibiting the replication
                                                                                                        Flavonoids                                                      MERS‐CoV                                      Act as antioxidant and antiviral compound, blocking the enzymatic activity of MERS‐CoV/3CLpro
                                                                          PLP inhibitors                SARS‐CoV                                                        Inhibit PLP of SARS‐CoV                       
                         S protein‐ACE2 blockers                          Human mAb                     SARS‐CoV                                                                                                      Neutralizing SARS‐CoV, inhibiting syncytia formation between cells expressing the S protein and the SARS‐CoV receptor ACE2
                                                                          Chloroquine                   SARS‐CoV                                                                                                      Possess antiviral effect, inhibiting of SARS‐CoV infection via interfering with ACE2
                                                                          Emodin                        SARS‐CoV                                                                                                      Blocking the interaction between the S protein of virus and ACE2
                                                                          Promazine                     SARS‐CoV                                                                                                      Inhibiting the replication of virus, inhibiting the binding of S protein to ACE2
                                                                          Nicotianamine                                                                                                                               Inhibiting the ACE2
  Antiviral treatments                                                    Ribavirin                     SARS‐CoV                                                                                                      Inhibiting the the replication of SARS‐associated CoV
                                                                          LPV/RTV (Kaletra)             HIV, SARS‐CoV, MERS‐CoV                                                                                       protease inhibitor
                                                                          RDV                           SARS‐CoV, MERS‐CoV                                                                                            Improving the pulmonary function, reducing the lung viral loads and severe lung pathology
                                                                          Nelfinavir                    HIV, SARS‐CoV                                                                                                 Act as selective inhibitor of HIV protease, Inhibiting the replication virus
                                                                          ARB                           influenza A/B, hepatitis C virus                                                                              Blocking viral fusion, entry and replication
                                                                          Nitric oxide                  SARS                                                                                                          Antiviral effects
  Other compounds                                                         ALA                           human CoV‐229E, HIV                                                                                           Act as antioxidant, inhibiting the replication of HIV‐1
                                                                          Estradiol and phytoestrogen   SARS‐CoV, MERS, influenza A                                                                                   Reducing virus replication in primary human nasal epithelial cells
                                                                          Mucroporin‐M1                 influenza H5N1 viruses, and SARS‐CoV                                                                          Virucidal activity against viruses
  ---------------------- ------------------------------------------------ ----------------------------- --------------------------------------------------------------- --------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: 3 CLpro, 3C‐like protease; Ab, antibody; ACE2, angiotensin converting enzyme 2; ALA, α‐lipoic acid; ARB, arbidol; CoV, coronavirus; CTM, Chinese traditional medicine; HIV, human immunodeficiency virus; IBV, bronchitis virus; IFN, interferons; IVIg, intravenous gammaglobulin; LPV/RTV, lopinavir/ritonavir; mAb, monoclonal antibody; PLpro, papain‐like protease; PUFA, polyunsaturated fatty acids; RDV, remdesivir; S, spike; Ta1, thymosin α‐1; TP5, thymopentin; Vit, vitamin.
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7.1. Chloroquine phosphate {#jcp29735-sec-0220}
--------------------------

Chloroquine phosphate is an old medicine, that has been widely used for treatment of malaria in endemic regions. It is also a salutary treatment of choice for certain progressive anti‐inflammatory diseases, for example, rheumatoid arthritis, and systemic lupus erythematosus. Recently, an investigation in China reported that remdesivir and chloroquine phosphate were effective experimental agents for controlling SARS‐CoV‐2 infection in the lab (Chen et al., [2013](#jcp29735-bib-0016){ref-type="ref"}). Initial findings reported by a recent study on effectiveness of therapeutic agents in management of SARS‐CoV‐2 infection, and suggested successful application of chloroquine phosphate in treatment of patients with COVID‐19‐associated pneumonia. Following the promising results, scientists recommended chloroquine phosphate to be included in treatment regimen of COVID‐19 patients with severe involvement of the lungs (Yu et al., [2013](#jcp29735-bib-0091){ref-type="ref"}). On February 15, 2020, participants from different organizations, including medical experts and authorities, made an agreement on potency of Chloroquine phosphate against SARS‐CoV‐2 infection (<https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/>).

So far, close monitoring of over 100 patients, who were under treatment of chloroquine phosphate, has provided further evidence regarding the effectiveness of this long‐known medicine. Investigations indicated that chloroquine phosphate prevented exacerbation of pneumonia in these patients, improved their chest CT findings, and shortened the otherwise long natural course of the disease. Importantly, there have been no records of severe reaction or hypersensitivity to this therapeutic agent. It has been suggested that the broad‐spectrum antiviral activity of chloroquine phosphate lies within the complicated pharmacodynamics of the drug that results in a basic shift in the endosomal pH required for successful fusion of virus onto the host cell. chloroquine phosphate also seems to have disruptive effects on glycosylation of cellular receptors of SARS‐CoV (Yin & Wunderink, [2018](#jcp29735-bib-0090){ref-type="ref"}; Zumla et al., [2020](#jcp29735-bib-0099){ref-type="ref"}), rendering them nonfunctional. It also interferes with activation of p38 mitogen‐activated protein kinase, a signaling event involved in replication of HCoV‐229E (Kono et al., [2008](#jcp29735-bib-0046){ref-type="ref"}).

7.2. Lopinavir/ritonavir, leronlimab, galidesivir {#jcp29735-sec-0230}
-------------------------------------------------

Lopinavir/Ritonavir, commonly used for treatment of HIV infection, has been indicated for treatment of COVID‐19 in a number of reports (Kim et al., [2020](#jcp29735-bib-0044){ref-type="ref"}). Previous studies suggested that when combined together, Lopinavir and Ritonavir act in concert to hinder further replication of SARS‐CoV, and improve the clinical status of patients with SARS (Chu et al., [2004](#jcp29735-bib-0022){ref-type="ref"}). This might also mean that the well‐known antiretroviral duo can also prove beneficial in treatment of COVID‐19.

Other candidates for possible management of SARS‐CoV‐2 include Leronlimab and Galidesivir, both of which have been of clinical value in treatment of several fatal viral infections, and were shown to improve the survival of patients. Leronlimab is a humanized monoclonal antibody (CCR5 antagonist). Galidesivir, on the other hand, belongs to the family of nucleoside RNA polymerase inhibitors (<https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/>). In the absence of any specific therapeutic agents to quell SARs‐CoV‐2, it might be a salutary strategy to repurpose the already available medicine, and include them in treatment of COVID‐19 (Tian et al., [2020](#jcp29735-bib-0069){ref-type="ref"}).

Several clinical trials can be viewed at [ClinicalTrials.gov](http://ClinicalTrials.gov), that are currently in progress. These trials have specially focused on potency of Remdesivir, immunoglobulins, and combinational therapies, for example, Arbidol hydrochloride with interferon atomization, ASC09F and oseltamivir, ritonavir and oseltamivir, and lopinavir combined with ritonavir (<https://clinicaltrials.gov/ct2/results?cond=&2019nCoV&term=&cntry=&state=&city=&dist=>).

7.3. RAAS inhibitors {#jcp29735-sec-0240}
--------------------

ACE2 is a prominent regulatory arm in the RAAS axis, thus, a disruption in ACE‐Angiotensin II‐Angiotensin Type 1 Receptor (AT1R), and ACE2/Angiotensin‐(1‐7)/Mas Receptor axes can result in multisystem inflammation. Increased levels of ACE and Angiotensin II in plasma are considered poor prognostic factors in severe pneumonia. Several studies on animal models have reported effectiveness of RAAS inhibitors in alleviation of severe pneumonia and acute respiratory failure. In the aftermath of SARS‐CoV‐2 and ACE2 binding, the enzyme is eventually degraded, hence, the inhibition of ACE2/Angiotensin‐(1‐7)/Mas Receptor pathway. Accordingly, it is assumed that ACE and AT1R inhibitors might be game‐changing agents that can especially be administered for COVID‐19 patients who have serious impairments in their homeostasis. Maintenance of homeostasis may ultimately result in suppression of the inflammatory response, mostly in the pulmonary tissue (Sun, Yang, Sun, & Su, [2020](#jcp29735-bib-0068){ref-type="ref"}).

7.4. Combination therapy {#jcp29735-sec-0250}
------------------------

Combination therapy is a more extensive and rigorous approach mainly aimed at correction of life‐threatening events such as shock, hypoxemia, secondary or super infection, and maintenance of homeostasis, that is, electrolyte, acid and base balance. As a palliative practice, antiviral treatment in the early stages of COVID‐19 might lessen the severity and prevent further progression of the disease. Trials on combination therapy with lopinavir/ritonavir and arbidol (umifenovir) have reported satisfactory results in treatment of COVID‐19. Alongside a proper antiviral treatment, patients may also benefit from an artificial liver blood purification system, which is capable of rapidly removing the inflammatory factors from blood, thus, halting the disastrous cytokine release syndrome. This system can also facilitate the sustenance of critically ill patients by preserving the balance of bodily fluid. Administration of glucocorticoids in moderate doses is another intervention that has recently been indicated for patients with severe COVID‐19‐associated pneumonia. However, secondary fungal infection should be considered. Patients with an oxygenation index of less than 200 mmHg might benefit more from oxygen therapy than noninvasive ventilation. A rational prescription of antimicrobial medicines has been cautioned only for patients with remittent fever and elevated antimicrobial prophylaxis should be prescribed rationally and was not recommended except for patients with long course of disease, repeated fever, and elevated PCT levels. Ultimately, to maintain the balance of intestinal microbiota, oral intake of prebiotics or probiotics has been suggested. This can reduce the risk of secondary infections as a result of microbial translocation; however, effectiveness of such interventions on postinfection clearance pattern of SARS‐CoV‐2 has not been studied (Xu et al., [2020](#jcp29735-bib-0086){ref-type="ref"}).

7.5. Other future possible options {#jcp29735-sec-0260}
----------------------------------

### 7.5.1. Convalescent blood therapy {#jcp29735-sec-0270}

A conspicuously conventional method, transfusion of human convalescent plasma, might be viewed as a beneficial strategy for prevention and even treatment of COVID‐19. The method is as facile as its age since it only requires an adequate number of recovered patients who are willing to donate their immunoglobulin‐containing serum. Although one still might argue the possibility of SARS‐CoV‐2 infection via convalescent blood transfusion, no such incident with SARS‐CoV was reported by WHO amidst the outbreak of the disease in 2003. The heft of past experience should come to mind once it is noted that the majority of approaches and therapeutic strategies that are currently being tested for COVID‐19 are derived from clinical experience in treatment of SARS, MERS, and other correspondents viral epidemics (Casadevall & Pirofski, [2020](#jcp29735-bib-0009){ref-type="ref"}; Cunningham, Goh, & Koh, [2020](#jcp29735-bib-0029){ref-type="ref"}).

### 7.5.2. Mesenchymal stem cell (MSC) therapy {#jcp29735-sec-0280}

A new therapeutic for treating immune‐mediated diseases, MSC therapy might have the capability to terminate the inappropriate release of cytokines in COVID‐19. Through its anti‐inflammatory effects, MSC therapy has been reported to improve respiratory function in murine models with acute lung injury. Evidence suggests that MSCs might be doing so by repressing the aberrant release of inflammatory factors (Hu & Li, [2018](#jcp29735-bib-0039){ref-type="ref"}; Wang, Yao, Lv, Ling, & Li, [2017](#jcp29735-bib-0071){ref-type="ref"}; Xiang et al., [2017](#jcp29735-bib-0085){ref-type="ref"}). In particular, a study by Chinese scientists concluded that transplantation of MSCs could be considered as a novel approach in treatment of viral pneumonia, noting promissory implications of this method in management of H7N9‐induced ARDS. Since H7N9 and SARS‐CoV‐2 can result in similar complications, for example, ARDS and respiratory failure, MSC‐based therapy might lead to a new path in treatment of COVID‐19‐associated pneumonia (Chen, Hu, et al., [2020](#jcp29735-bib-0012){ref-type="ref"}).

### 7.5.3. Nano drug delivery systems {#jcp29735-sec-0290}

It has long been known that the traditional circulation‐based delivery of therapeutic agents is not as effect, prompting pharmaceutical industries to develop novel platforms for delivery of molecules to hard‐to‐reach tissues in human body. Conjugation of antiviral agents, particularly nucleoside analogs, with specific nanoparticles has proved to be effectual in treatment of resistant HIV infection (Agarwal, Chhikara, Doncel, & Parang, [2017](#jcp29735-bib-0002){ref-type="ref"}; Agarwal, Chhikara, Quiterio, Doncel, & Parang, [2012](#jcp29735-bib-0003){ref-type="ref"}). Today, an appreciable number of drug delivery platforms based on nanotechnology are available that can be experimentally used with custom therapeutic formulations for treatment of COVID‐19 (Chhikara & Varma, [2019](#jcp29735-bib-0020){ref-type="ref"}) in hopes of shortening the course of the disease (Chhikara et al., [2020](#jcp29735-bib-0019){ref-type="ref"}).

### 7.5.4. Psychological interventions {#jcp29735-sec-0300}

Progression of COVID‐19, similar to any other disease, can result in suffering of the patients, prompting psychological symptoms, which will require special interventions. It has been well‐established today that individuals who fall victim to public health emergencies, for example, disease outbreaks, develop variable degrees of stress disorders. The problem persists even after the individual has recovered and discharged from the hospital (Cheng, Wong, Tsang, & Wong, [2004](#jcp29735-bib-0018){ref-type="ref"}; Fan, Long, Zhou, Zheng, & Liu, [2015](#jcp29735-bib-0031){ref-type="ref"}). With that in mind, one should consider several factors for classification of patients who will most probably benefit from psychological interventions; that is overall course of the disease, severity, and quality of hospitalization (e.g., home, ordinary wards, ICU, etc.) (Duan & Zhu, [2020](#jcp29735-bib-0030){ref-type="ref"}).

In large‐scale outbreaks such as COVID‐19 epidemic, healthcare workers become the frontline at providing psychological cares for patients who battle against the disease. Primary medical and mental care should be provided for those individuals who are recognized as "suspected case" and duly quarantined at home. (Duan & Zhu, [2020](#jcp29735-bib-0030){ref-type="ref"}).

Interventions should be discreetly formulated following a thorough evaluation of risk factors involved in emerging of these psychological issues, including a history of impaired mental health, bereavement after a deceased family member, panic, separation from loved ones, and a low income (Kun, Han, Chen, Yao, & Anxiety, [2009](#jcp29735-bib-0047){ref-type="ref"}).

8. PATIENTS RECOVERED FROM COVID‐19 {#jcp29735-sec-0310}
===================================

The following criteria must be met in order for a patient to be discharged from hospital or released from quarantine: (a) having been afebrile for at least 3 consecutive days, (b) remission of respiratory distress, (c) regression of infiltrations/consolidations on chest CT images, and two consecutive negative reports of RT‐PCR test performed at least 1 day apart (d). Despite these thoroughly formulated criteria, one study reported positive RT‐PCR test results 5--13 days after hospital discharge for four patients with COVID‐19, who met all of the criteria above before they were discharged. These findings are important in that they imply the slight possibility that even a fully recovered patient might still be a silent carrier of the virus. In this scenario, however, no family members were reported to be infected, since all of the four patients with bizarrely late positive tests were medical professional, and followed all of the guidelines while they were at home quarantine. With due attention to this incident, the current criteria for hospital discharge may need to be reconsidered (Lan et al., [2020](#jcp29735-bib-0049){ref-type="ref"}).

9. CONCLUSIONS AND FUTURE PERSPECTIVES {#jcp29735-sec-0320}
======================================

Deemed a global health emergency, COVID‐19 outbreak has continued to be the headline of the news. The number of confirmed cases is on the rise, and the seamless spread of the virus has become a plight for general population, and the entire medical community. In spite of the extreme preventive measures while near a patient, clinicians are still at great risk for contracting the disease from the visitors. Else, it is vividly known that quarantine alone is not the optimal choice for containing of the virus. On the other hand, the devastating potential impact of the outbreak is a much feared topic around the world. Science has always been the ultimate arsenal of weaponry when it comes to battling obstinate pathogens; however, time is needed for conduction of proper investigations on human‐to‐human and animal‐to‐human transmission of SARS‐CoV‐2.

With no access to requisite information on the structure and life cycle of the novel Coronavirus, research and development programs on therapeutic agents become a far‐fetched milestone, rendering the tried‐and‐true primary prevention measures the only proper means to confront SARS‐CoV‐2. As of today, few existing drugs have been considered for treatment of COVID‐19, with scant reports on benevolence of the results. As our meager knowledge of SARS‐CoV‐2 is advancing, one may speculate the advent of an effectual vaccine, alongside treatment options that might include antiviral agents, and even monoclonal antibodies. At the time of writing this manuscript, no definitive treatment option has been known for COVID‐19; however, the unabating flow of investigations and clinical trials may soon lead us to the optimal therapy for COVID‐19‐associated pneumonia.

Needless to say, the fascinatingly high transmissibility of COVID‐19 demands meticulous monitoring of the transmission routes and patterns to a reach a firm theory on adaptive mechanisms wielded by SARs‐CoV‐2, thus, making an accurate prediction about the future outcomes regarding pathogenicity, transmissibility, and evolution of the virus. These efforts will hopefully result in better prognosis and fewer mortalities.
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